cytarabine has been researched along with melphalan in 561 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (13.01) | 18.7374 |
| 1990's | 114 (20.32) | 18.2507 |
| 2000's | 169 (30.12) | 29.6817 |
| 2010's | 173 (30.84) | 24.3611 |
| 2020's | 32 (5.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chhabra, J; Kumar, R; Narang, R; Pahwa, R | 1 |
| Banerjee, A; Benedict, WF; Gardner, A; Jones, PA | 1 |
| Cohen, HJ; Rundles, RW | 1 |
| Brown, SG; Parsons, PG | 1 |
| Emmerich, B; Maurer, R; Rastetter, J; Schmidt, G | 1 |
| Bergsagel, DE | 2 |
| Blok, J; Cleton, FJ; de Waal, FC; Mulder, E; Smets, LA | 1 |
| Håkansson, L | 1 |
| Bergsagel, DE; Librach, SL; Ogawa, M | 1 |
| Freireich, EJ; Gottlieb, JA; Loo, TL; Mahagaokar, S; Rao, PN | 1 |
| Dencker, H; Håkansson, L; Tropé, C | 1 |
| Adam, M; Baruchel, A; Brice, P; Dombret, H; Gisselbrecht, C; Lepage, E; Marolleau, JP; Miclea, JM; Sitthy, X | 1 |
| Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B | 1 |
| Arya, R; Brito-Babapulle, F; Griffiths, T; Mufti, GJ; Pagliuca, A | 1 |
| Weiss, RB | 1 |
| Copelan, EA | 1 |
| Janmohammed, RM; Leyland, MJ; Long, SG; Macdonald, DF; Milligan, DW; Smith, AG | 1 |
| Schaison, GS | 1 |
| Russell, S; Vowels, M | 1 |
| Blair, S; Cervi, P; Chopra, R; Goldstone, AH; Kinsey, S; Linch, DC; McMillan, AK; Moir, D; Patterson, KG; Richards, JD | 1 |
| Douay, L; Eugene-Jolchine, I; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A; Stachowiak, J | 1 |
| Ascari, E; Danova, M; Giordano, M; Invernizzi, R; Luoni, R; Rastaldi, MP; Riccardi, A; Ucci, G; Zambelli, ML | 1 |
| Bastion, Y; Coiffier, B; Tigaud, JD | 1 |
| Cheung, NK; Exelby, PR; Gulati, SC; Kushner, BH; Kwon, JH; O'Reilly, RJ | 1 |
| Frankfurt, OS | 1 |
| Goldstone, A; McMillan, A | 1 |
| Benz-Lemoine, E; Bergerat, JP; Bordigoni, P; Cahn, JY; Colombat, P; Lutz, P; Pico, JL; Plouvier, E; Reiffers, J; Souillet, G | 1 |
| Biron, P; Cahn, JY; Colombat, P; Gorin, NC; Herve, P; Lamagnere, JP; Laporte, JP; Philip, T | 1 |
| Brandwein, JM; Callum, J; Keating, A; Scott, JG; Sutcliffe, SB | 1 |
| Ehrsson, H; Eksborg, S | 1 |
| Markman, M | 3 |
| Iwabuchi, M; Takahashi, K | 1 |
| Bigner, DD; Friedman, HS; Schold, SC | 1 |
| Bisson, M; Massias, P; Paule, B; Quillard, J | 1 |
| Douay, L; Fouillard, L; Gorin, NC; Isnard, F; Laporte, JP; Najman, A | 1 |
| Bregni, M; Gianni, AM; Siena, S; Tarella, C | 1 |
| Devereaux, S; Goldstone, AH; Gribben, JG; Linch, DC; McMillan, A; Patterson, K | 1 |
| Bernasconi, C | 1 |
| Alexanian, R; Barlogie, B; Cabanillas, F; Velasquez, WS | 1 |
| Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ | 1 |
| Engeset, A; Sønstevold, A; Tanum, G | 1 |
| Ishikawa, E; Kawakami, M; Kuraishi, Y; Meguro, S; Tanaka, H | 1 |
| Nakada, H; Takahashi, I | 1 |
| Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ | 1 |
| Linch, DC; Singer, CR | 1 |
| Anderson, CC; Cawley, JC; Goldstone, AH; Harper, PG; Jelliffe, AM; Jones, M; Linch, DC; Machin, SJ; McLennan, KA; Souhami, RL | 1 |
| Appelbaum, FR; Buckner, CD | 1 |
| Lampkin, BC; Wong, KY | 1 |
| Brenner, DE | 1 |
| Gassmann, W; Kayser, W; Löffler, H; Schmitz, N | 1 |
| Alberts, DS; Mason, N; Salmon, SE; Young, L | 1 |
| Bierling, R | 1 |
| Keane, WM; Khaleeli, M; Lee, GR | 1 |
| Demeulenaere, L; Hamers, J; Van Hove, W | 1 |
| Nordquist, RE; Shaw, MT; Twele, TW | 1 |
| Abendroth, K; Siering, VH | 1 |
| Jacobs, EM; Johnson, FD | 1 |
| Bhuyan, BK; Fraser, TJ; Scheidt, LG | 1 |
| Zubrod, CG | 1 |
| Davies, DA | 1 |
| Frei, E; Goldin, A; Schabel, FM | 1 |
| Parker, AC | 1 |
| Dominick, CA; Dykes, DJ; Griswold, DP; Kelley, CA; Roberts, BJ | 1 |
| Bayrd, ED; Kyle, RA; Pierre, RV | 1 |
| Carter, SK | 1 |
| Håkansson, L; Tropé, C | 4 |
| Berndt, H; Rieche, K | 1 |
| Ravina, A | 1 |
| Cornwell, GG; McIntyre, OR; Mills, RC | 1 |
| Cohen, SL; Dodsworth, H; Whitelaw, AG | 1 |
| Clifford, P; Klein, G; Singh, S; Stjernswärd, J | 1 |
| Meistrich, ML; Meyn, RE; White, RA | 1 |
| Dantas, M; Drebing, C; Glode, LM; Koeppler, H; Robinson, WA; Thomas, MR | 1 |
| Hill, DL; Montgomery, JA | 1 |
| Balconi, G; D'Incalci, M; Erba, E; Garattini, S; Morasca, L; Ottolenghi, L; Salmona, A | 1 |
| Akerman, M; Biörklund, A; Håkansson, L; Stenstam, B; Tropé, C | 1 |
| Daguenel, A; Gorin, NC; Laporte, JP; Lesage, S; Najman, A; Parlier, Y; Woler, M | 1 |
| Bassan, R; Bellavita, P; Borleri, GM; Buelli, M; Comotti, B; Cortelazzo, S; Marziali, S; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE | 1 |
| Dranitsaris, G; Sutcliffe, SB | 1 |
| Dreger, P; Haferlach, T; Klöss, M; Loeffler, M; Löffler, H; Petersen, B; Schmitz, N | 1 |
| Bastion, Y; Brice, P; Coiffier, B; Espinouse, D; Gisselbrecht, C; Haioun, C; Marolleau, JP; Reyes, F; Salles, G; Sonet, A | 1 |
| Allen, PD; Castenskiold, EC; Coldwell, RD; Collins, PW; Goldstone, AH; Kelsey, SM; Makin, HL; Newland, AC; Side, LE | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Baruchel, A; Devergie, A; Esperou Bourdeau, H; Hirsch, I; Moussalem, M; Parquet, N; Ribaud, P; Schaison, G; Socie, G; Traineau, R | 1 |
| Hirano, M; Kojima, S; Miyamura, K; Morishima, Y; Morishita, Y; Ohno, R; Sao, H; Sobue, R; Tanimoto, M; Ueda, R | 1 |
| Dreger, P; Eckstein, V; Haferlach, T; Jacobs, S; Löffler, H; Marquardt, P; Müller-Ruchholtz, W; Mülverstedt, T; Schmitz, N; Suttorp, M | 1 |
| Chatterjee, R; Goldstone, AH; Katz, M; McGarrigle, HH; Mills, W | 2 |
| Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
| Goldstone, AH; Khwaja, A; Linch, DC | 1 |
| Phillips, GL; Reece, DE | 1 |
| Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, A; Mills, W; Pearce, R | 1 |
| Brice, P; Castaigne, S; Gisselbrecht, C; Marolleau, JP; Pautier, P | 1 |
| Canellos, GP; Griffin, JD; Matulonis, UA | 1 |
| Baybordi, E; Ghavamzadeh, A; Jahani, M | 1 |
| Attal, M; Brousset, P; Dastugue, N; Demur, C; Duchayne, E; Rigal-Huguet, F; Robert, A; Rubie, H | 1 |
| Barbot, C; Jazwiec, B; Mahon, FX; Reiffers, J; Rice, A; Vanès, I | 1 |
| Chopra, R; Goldstone, AH; Hancock, B; Hudson, GV; Linch, DC; McMillan, A; Milligan, D; Moir, D; Winfield, D | 1 |
| Dreger, P; Gassmann, W; Glass, B; Haferlach, T; Horst, HA; Löffler, H; Ollech-Chwoyka, J; Schmitz, N; Suttorp, M | 1 |
| Brosteanu, O; Haas, R; Hasenclever, D; Kirchner, H; Koch, P; Kuse, R; Lathan, B; Pfreundschuh, MG; Rueffer, U; Schmitz, N | 1 |
| Bairey, OS; Sandbank, Y; Shaklai, M | 1 |
| Lundström, U; Pesonen, E; Pihkala, J; Saarinen, UM; Salmo, M; Siimes, MA; Virkola, K; Virtanen, K | 1 |
| Fukatani, H; Kiyoi, H; Kojima, S; Kubo, K; Naoe, T; Ohno, R; Yamauchi, T | 1 |
| Barnett, MJ; Connors, JM; Klingemann, HG; O'Reilly, SE; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Chopra, R; Goldstone, AH; Linch, DC; McMillan, AK; Patterson, KG; Pearce, R; Taghipour, G; Yuklea, S | 1 |
| Smith, RJ; Sweetenham, JW | 1 |
| Heinemann, V; Jehn, U; Pötscher, C | 1 |
| Goldstone, AH; Linch, DC; Mills, W; Strang, J | 1 |
| Barge, A; Boogaerts, MA; Demuynck, HM; Dreger, P; Ferrant, A; Goldstone, AH; Linch, DC; Link, H; Schmitz, N; Zander, A | 1 |
| Bhargava, M; Kumar, R; Raina, V; Sharma, A | 1 |
| Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B | 1 |
| Billingham, LJ; Knechtli, CJ; Long, SG; Lumley, MA; McDonald, DF; Milligan, DW | 1 |
| Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA | 1 |
| Ma, L; Qiao, Z; Wang, C; Yang, L; Zhang, H; Zhang, J | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Buelli, M; Comotti, B; Cortelazzo, S; Fracassetti, D; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Haynes, AP; Iqbal, A; McQuaker, IG; Russell, NH | 1 |
| de Kreuk, AM; Dräger, AM; Huijgens, PC; Jonkhoff, AR; Legdeur, MC; Oberink, JW; Ossenkoppele, GJ; Schuurhuis, GJ; Westra, G; Zweegman, S | 1 |
| Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K | 1 |
| Fielding, AK; Goldstone, AH; Jamieson, E; Linch, DC; Sullivan, AM; Watts, MJ | 1 |
| Berdel, WE; Hoppe, B; Knauf, WU; Koenigsmann, MP; Notter, M; Oberberg, D; Reufi, B; Thiel, E | 1 |
| Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Barbui, T; Bassan, R; Bellavita, P; Comotti, B; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Amigo, ML; Caballero, MD; del Cañizo, C; García, R; Gonzalez, M; Hernández, JM; San Miguel, JF; Vazquez, L | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Betts, E; Goebel, ME; Honegger, H; Jost, LM; Nagler, A; Stahel, RA | 1 |
| Anderson, L; Linch, DC; Vaughan Hudson, B; Vaughan Hudson, G | 1 |
| Bartels, H; Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Batan, ZE; Milanovich, NF; Skriagin, AE; Snegir', VM; Uss, AL; Zmachinskiĭ, VA | 1 |
| Mizoguchi, H; Wada, M | 1 |
| Hoyt, DG; Kondo, Y; Lazo, JS; Pitt, BR; Rusnak, JM; Settineri, CE | 1 |
| Brandwein, J; Crump, M; Dufresne, J; Girouard, C; Imrie, K; Keating, A; Pantolony, D; Prince, HM; Stewart, AK | 1 |
| Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B | 1 |
| Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J | 1 |
| Barbui, T; Bellavita, P; Cortelazzo, S; Marchioli, R; Marfisi, RM; Rambaldi, A; Rossi, A; Viero, P | 1 |
| Caballero, D; del Cañizo, C; García-Sanz, R; González, M; Heras, I; Jean-Paul, E; León, A; Pérez-Simón, JA; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vicente, V; Vidriales, B | 1 |
| Bordigoni, P; Cahn, JY; Caillot, D; Cordonnier, JM; Deconinck, E; Esperou, H; Hervé, P; Jouet, JP; Leblond, V; Lioure, B; Milpied, N; Troussard, X; Vernant, JP | 1 |
| de Wolf, JT; Hovenga, S; Klip, H; Vellenga, E | 1 |
| Andreeva, LA; Batan, ZE; Chervonobab, IuV; Chimishkian, KL; Demina, EA; Kondrat'eva, NE; Larionova, VB; Milanovich, NF; Mkheidze, DM; Ptuskin, VV; Snegir', VM; Tupitsyn, NN; Uss, AL; Zmachinskiĭ, VA | 1 |
| Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC | 1 |
| Devereux, S; Goldstone, AH; Leverett, D; Linch, DC; Peniket, AJ; Perry, AR; Sullivan, AM; Watts, MJ; Williams, CD | 1 |
| Cooper, DL; D'Andrea, E; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Azaceta, G; Palomera, L; Soria, J; Varo, MJ | 1 |
| Diehl, V; Engert, A; Josting, A; Kàtay, I; Rueffer, U; Tesch, H; Wickramanayake, PD; Winter, S | 1 |
| Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB | 1 |
| Buckner, CD; Weaver, CH; Zhen, B | 1 |
| Dreger, P; Glass, B; Kuse, R; Löffler, H; Schmitz, N; Schoch, R; Sonnen, R; Uharek, L; von Neuhoff, N | 1 |
| Bulabois, CE; Colombat, P; Dupas, B; Harousseau, JL; Juge-Morineau, N; Mahé, B; Milpied, N; Moreau, A; Moreau, P; Rapp, MJ; Voillat, L | 1 |
| Cunningham, D; Popescu, RA; Wotherspoon, AC | 1 |
| Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W | 1 |
| Andreu, G; Aoudjhane, M; Bauters, F; Belkacemi, Y; Cheron, N; Douay, L; Fenaux, P; Fouillard, L; Gorin, NC; Isnard, F; Jouet, JP; Labopin, M; Laporte, JP; Lemonnier, MP; Lesage, S; Lopez, M; Morel, P; Najman, A; Noël-Walter, MP; Stachowiak, J; Zunic, P | 1 |
| Bordigoni, P; Boutard, P; Cornu, G; Esperou, H; Gandemer, V; Gratecos, N; Jouet, JP; Lacour, B; Leverger, G; Lutz, P; Michel, G; Milpied, N; Pico, J; Plouvier, E; Reiffers, J; Rohrlich, P; Rubie, H; Sadoun, A; Souillet, G; Stephan, JL; Vannier, JP; Vernant, JP | 1 |
| Fehse, N; Gutensohn, K; Hassan, HT; Kröger, N; Krüger, W; Lölliger, C; Zander, AR; Zeller, W | 1 |
| Amigo, ML; del Cañizo, MC; Gonzalez, MB; Gutiérrez, N; Hernández, JM; Mateos, MV; San Miguel, JF | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Rukavitsyn, OA | 1 |
| Anaissie, E; Ayers, D; Barlogie, B; Cheson, B; Cromer, J; Crowley, J; Desikan, KR; Dhodapkar, D; Epstein, J; Fassas, A; Jagannath, S; Mattox, S; Mehta, J; Munshi, N; Naucke, S; Sawyer, J; Siegel, D; Singhal, S; Spoon, D; Tricot, G; Vesole, D | 1 |
| Barta, A; Batai, A; Kelemen, E; Lengyel, L; Paloczi, K; Petranyi, GG; Sipos, A; Torbagyi, E | 1 |
| Bamborschke, S; Diehl, V; Feiden, W; Lehrke, R; Re, D; Schröder, R; Tesch, H | 1 |
| Burtness, B; Cooper, DL; Hu, GL; Jillella, AP; Nadkarni, R; Salloum, E; Seropian, S; Zelterman, D | 1 |
| Dias Wickramanayake, P; Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Scheid, C; Tesch, H; Wolf, J | 1 |
| Anderlini, P; Andersson, B; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Folloder, J; Gajewski, J; Giralt, S; Hagemeister, F; Khouri, I; Körbling, M; Mehra, R; Molldrem, J; Przepiorka, D; Samuels, B; Ueno, NT; van Besien, K | 1 |
| Cuesta, B; Panizo, C; Rifón, J; Rocha, E; Rodríguez-Wilhelmi, P | 1 |
| Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D | 1 |
| Aguado, MJ; Canales, MA; de Bustos, JG; Fernández-Jiménez, MC; Hernández-Navarro, F; Ojeda, E | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Buijt, I; Huijgens, PC; Ossenkoppele, GJ; Uyl-de Groot, CA | 1 |
| Bourhis, JH; Brice, P; Brousse, N; Decaudin, D; Gisselbrecht, C; Haioun, C; Morel, P; Quesnel, B; Souleau, B; Van Hoof, A | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Marecková, H; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Diehl, V; Draube, A; Engert, A; Josting, A; Reiser, M; Rueffer, U; Söhngen, D; Tesch, H; Wickramanayake, PD; Wolf, J | 2 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Byrne, JL; Carter, GI; Cull, GM; Hale, G; Haynes, AP; Miflin, G; Rebello, P; Russell, NH; Waldmann, H | 1 |
| Abdallah, A; Haas, R; Ho, AD; Hohaus, S; Martin, S; Schlenk, RF; Voso, MT | 1 |
| Bruty, SJ; Duncombe, AS; George, P; Sweetenham, JW; Wyre, RM | 1 |
| Beauséjour, CM; Cournoyer, D; Delisle, JS; Létourneau, S; Momparler, RL; Palerme, JS | 1 |
| Buthmann, U; Freund, M; Kleine, HD; Volk, J | 1 |
| Brion, A; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Foussard, C; Gaillard, F; Lamy, T; Lemevel, A; Milpied, N | 1 |
| Clowes, C; Duarte, R; Pu, QQ; Wang, X | 1 |
| Argiris, A; Cooper, DL; Seropian, S | 1 |
| Björkholm, M; Gruber, A; Hansson, M; Steingrimsdottir, H; Svensson, A | 1 |
| Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL | 1 |
| de Vries, P; Singer, JW | 1 |
| Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE | 1 |
| Carreras, E; Esteve, J; Fernández, F; Martínez, C; Montserrat, E; Perales, M; Rovira, M; Urbano-Ispizua, A | 1 |
| Acholonu, S; Anderlini, P; Andersson, B; Cabanillas, F; Champlin, RE; Cohen, A; Giralt, S; Hagemeister, F; Khouri, I; Körbling, MJ; Manning, J; Mclaughlin, P; Romaguera, J; Sarris, A; Ueno, NT | 1 |
| Jantunen, E; Mahlamäki, E; Nousiainen, T | 1 |
| Berger, M; Boiret, N; Deméocq, F; Halle, P; Kanold, J; Malpuech, G; Paillard, C; Rapatel, C; Yakouben, K | 1 |
| Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O | 1 |
| Blaise, D; Caraux, J; Chabannon, C; Faucher, C; Maraninchi, D; Vey, N | 1 |
| Carella, AM; Cavaliere, M; Corsetti, MT; De Stefano, F; Ferrara, R; Lambelet, P; Lerma, E; Loni, C; Pinotti, G; Romanelli, A; Tedeschi, L; Valbonesi, M; Verdiani, S; Vinci, M | 1 |
| Dobie, D; Hastings, M; Mahendra, P; Richardson, G; Tauro, S | 1 |
| Klener, P; Procházka, B; Slabý, J; Trnený, M | 1 |
| Aplan, PD; Ploski, JE | 1 |
| Bouafia, F; Coiffier, B; Dumontet, C; Espinouse, D; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Ma, Y; Qiao, Z; Yang, L | 1 |
| Feng, S; Han, M; Li, C | 1 |
| Beham-Schmid, C; Hoefler, G; Linkesch, W; Neumeister, P; Sill, H | 1 |
| Aleĭnikova, OV; Batan, ZE; Dziuba, EV; Milanovich, NF; Mitskevich, PB; Skriagin, AE; Solov'eva, NS; Uss, AL; Vlasenkova, SV; Zavgorodniaia, IL; Zhavrid, EA; Zmachinskiĭ, VA | 1 |
| Caballero, MD; Canales, MA; Fernández-Jiménez, MC; García de Bustos, J; Hernández-Navarro, F; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Gregora, E; Havrdová, E; Kobylka, P; Kozák, T; Maaloufová, J; Pit'ha, J; Pytlík, R; Vodvárková, S | 1 |
| Diehl, V; Ehninger, G; Franklin, J; Hasenclever, D; Kirchner, H; Koch, P; Lathan, B; Loeffler, M; Pfreundschuh, M; Rueffer, U; Schmitz, N; Sextro, M; Tesch, H | 1 |
| Barbui, T; Bassan, R; Borleri, G; Broccia, G; Casula, P; Corneo, G; Cortelezzi, A; Coser, P; Fabris, P; Izzi, T; Lambertenghi-Deliliers, G; Lerede, T; Morandi, S; Pogliani, E; Rambaldi, A; Rossi, G; Spedini, P; Vespignani, M | 1 |
| Filippi, M; Gualandi, F; Inglese, M; Lugaresi, A; Mancardi, GL; Marmont, A; Marrosu, MG; Massacesi, L; Meucci, G; Murialdo, A; Pagliai, F; Saccardi, R; Sardanelli, F; Sormani, MP | 1 |
| Dreger, P; Glass, B; Kuse, R; Schmitz, N; Seyfarth, B; Sonnen, R | 1 |
| Kashyap, A; Snowden, J | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| Inwards, DJ; Lacy, MQ; Markovic, SN; Porrata, LF | 1 |
| Blystad, AK; Delabie, J; Holte, H; Kvalheim, G; Kvaløy, S; Smeland, E | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Berger, F; Brice, P; Colin, P; Diviné, M; Fermé, C; Jaubert, J; Lederlin, P; Mounier, N; Reman, O; Salles, G; Stamatoullas, A; Voillat, L | 1 |
| Becherer, A; Dudczak, R; Greinix, HT; Jaeger, U; Kalhs, P; Karanikas, G; Kletter, K; Mitterbauer, M; Pötzi, C; Raderer, M | 1 |
| Ariatti, C; Bertini, M; Boccomini, C; Botto, B; Calvi, R; Capello, D; Carbone, A; Freilone, R; Gaidano, G; Gallo, E; Gloghini, A; Milan, I; Novero, D; Orsucci, L; Palestro, G; Parvis, G; Pregno, P; Saglio, G; Vitolo, U; Vivenza, D; Zagonel, V | 1 |
| Dreger, P; Glass, B; Haas, R; Kneba, M; Kröger, N; Kuse, R; Martin, S; Parwaresch, R; Schmitz, N; Sonnen, R | 1 |
| Barbui, T; Bassan, R; Carter, M; Casula, P; Di Bona, E; Fabris, P; Lambertenghi-Deliliers, G; Lerede, T; Lister, TA; Morandi, S; Pogliani, E; Rambaldi, A; Rohatiner, AZ; Rossi, G | 1 |
| Clark, AD; Cook, G; Douglas, KW; Franklin, IM; McQuaker, IG; Mitchell, LD; Parker, AN; Tansey, PJ | 1 |
| Boissevain, F; Carella, AM; Decker, S; Diehl, V; Goldstone, AH; Haenel, M; Hasenclever, D; Kirchner, H; Koch, B; Lohri, A; Müller, P; Pfistner, B; Schmitz, N; Sextro, M; Sieber, M; Zschaber, R | 1 |
| Buerger, T; Gebauer, T; Halloul, Z; Meyer, F | 1 |
| Clemente González, C; García Parés, D; García-Bragado Dalmau, F; Guardia Sánchez, R; Pérez Ayuso, MJ; Porcar Ramells, C | 1 |
| Elonen, E; Franssila, K; Itälä, M; Jantunen, E; Kuittinen, O; Lehtinen, T; Oinonen, R; Wiklund, T | 1 |
| Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH | 1 |
| Bataille, R; Harousseau, JL; Mahé, B; Milpied, N; Misbahi, R; Moreau, P; Morineau, N; Rapp, MJ; Vigier, M | 1 |
| Gallet, B; Genet, P; Jondeau, K; Laribi, K; Lionnet, F; Pulik, M; Touahri, T | 1 |
| Engert, A; Glossmann, JP; Josting, A; Paulus, U; Pfistner, B | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Abel, U; Baudis, M; Birkmann, J; Bischoff, HG; Franke, A; Grundeis, M; Havemann, K; Hossfeld, DK; Kaiser, U; Karakas, T; Kneba, M; Köppler, H; Krahl, D; Mantovani, L; Mesters, RM; Metzner, B; Müller, P; Parwaresch, R; Pfab, R; Pfreundschuh, M; Reiser, M; Rothmann, F; Schmalenberg, H; Schmitz, N; Schumacher, K; Steinhauer, EU; Trümper, L; Uebelacker, I; von Seydewitz, CU | 1 |
| Aleĭnikova, OV; Pochetukhin, KV; Strongin, IuS | 1 |
| Albó, C; Arranz, R; Caballero, MD; Cabrera, R; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García Ruíz, JC; García-Conde, J; García-Laraña, J; Grande, C; Iriondo, A; Lahuerta, JJ; Marín, J; Moraleda, JM; Pérez-Equiza, C; Pérez-Simón, JA; Rifón, J; Rubio, V; San Miguel, JF; Sierra, J; Sureda, A; Varela, R; Vidal, MJ; Zuazu, J | 1 |
| Afanas'ev, BV; Alekseeva, IuA; Medvedeva, NV; Mikhaĭlova, NB; Zaritskiĭ, AIu; Zubarovskaia, LS | 3 |
| García, J; Lahuerta, JJ; Lizasoain, M; Sanz, F | 1 |
| del Palacio, A; Garau, M; Molina, L; Relaño, MT | 1 |
| Cooney, JP; Parthasarathy, M; Stiff, PJ; Toor, AA | 1 |
| Barbui, T; Benedetti, F; Capria, S; Carlo-Stella, C; Corradini, P; Cortelazzo, S; Di Nicola, M; Gianni, AM; Magni, M; Martelli, M; Parvis, G; Patti, C; Pilotti, S; Rambaldi, A; Tarella, C | 1 |
| Jaffrey, I; Pashaei, S; Ryder, J; Sun, T | 1 |
| Grøttum, P; Kvalheim, G; Rusten, LS; Østby, I | 1 |
| Jantunen, E; Kuittinen, T; Nousiainen, T | 1 |
| AMALRIC, R; CLEMENT, R | 1 |
| BACHMAN, CH; DAVIS, HW; GELORMINI, OJ | 1 |
| QUICK, D; RICHMOND, JD | 1 |
| DE VULPIAN, P | 1 |
| PIGNATARO, E | 1 |
| CHAUNDY, CJ | 1 |
| HENCEK, M; ZACHAR, J | 1 |
| MAHFOUZ, MM | 1 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Abrey, LE; Anderson, ND; Caron, D; Correa, DD; Crump, M; DeAngelis, LM; Forsyth, P; Mason, WP; Moskowitz, CH; Nimer, SD; Paleologos, N; Stewart, D; Zelenetz, A | 1 |
| Arranz, R; Caballero, MD; Carreras, E; Conde, E; Fernández de Sevilla, A; Gandarillas, M; García-Laraña, J; Gutiérrez, A; Lahuerta, JJ; León, A; Marín, J; Rifon, J; Rodríguez, J; SanMiguel, J; Sureda, A; Varela, R; Zuazu, J | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Berthou, C; Colombat, P; Deconinck, E; Delwail, V; Foussard, C; Gaillard, F; Gressin, R; Harousseau, JL; Lucas, V; Milpied, N | 1 |
| Blystad, AK; Delabie, J; Holte, H; Ikonomou, I; Kvalheim, G; Kvaløy, S; Vålerhaugen, H | 1 |
| Ball, ED; Bashey, A; Carrier, E; Chen, YA; Corringham, S; Holman, P; Wang, EH | 1 |
| Cailliot, C; Fouillard, L; Gorin, NC; Isnard, F; Labopin, M; Laporte, JP; Lesage, S; Najman, A; Yeshurun, M | 1 |
| Caballero, MD; Cañizo, MC; López-Holgado, N; Martín, A; Mateos, MV; Miguel, JF; Pérez-Simón, JA | 1 |
| Berlier, P; Berthier, JC; Bertrand, Y; Bleyzac, N; Bruno, B; Contamin, B; Dai, QY; David, M; Galambrun, C; Homole, E; Manel, AM; Massenavette, B; Pages, MP; Philippe, N; Souillet, AL; Souillet, G | 1 |
| Assari, S; Bennaceur, AL; Boccaccio, C; Bonnet, ML; Bourhis, JH; Decaudin, D; Farace, F; Greissenger, N; Guillier, M; Marracho, MC; Michon, J; Némati, F; Turhan, AG; Vantelon, JM | 1 |
| Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
| Ardito, R; Cammarota, A; Di Renzo, N; Gallucci, G; Romano, G; Tartarone, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, G; Enke, C; Hankins, J; Lynch, JC; Vose, JM | 1 |
| Bosi, A; Bruzzi, P; Di Bartolomeo, P; Donelli, A; Filippi, M; Gualandi, F; Guerrasio, A; La Nasa, G; Mancardi, GL; Marmont, AM; Murialdo, A; Pagliai, F; Papineschi, F; Saccardi, R; Scappini, B; Solari, A | 1 |
| Berdel, WE; Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Hossfeld, DK; Josting, A; Kirchner, HH; Kisro, J; Mapara, M; Metzner, B; Rudolph, C; Sieber, M; Sienawski, M; Sieniawski, M | 1 |
| Caballero, MD; del Cañizo, MC; López-Holgado, N; Martín, A; Pérez-Simón, JA; San Miguel, JF; Vázquez, L | 1 |
| Boruczkowski, D; Choma, M; Chybicka, A; Drabko, K; Gorczyńska, E; Kałwak, K; Kowalczyk, JR; Pieczonka, A; Toporski, J; Turkiewicz, D; Wachowiak, J; Wójcik, B; Zaucha-Prazmo, A | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Bocková, J; Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Vokurka, S | 1 |
| Acholonu, S; Anderlini, P; Champlin, RE; Couriel, D; De Lima, M; Donato, ML; Fayad, L; Giralt, S; Hosing, C; Jones, R; Khouri, IF; Korbling, M; Maadani, F; Manning, JT; McLaughlin, P; Okoroji, GJ; Pro, B; Saliba, RM; Shpall, E; Younes, A | 1 |
| Diehl, V; Dörken, B; Engert, A; Glossmann, JP; Josting, A; Kisro, J; Ko, Y; Mapara, M; Metzner, B; Nogova, L; Peters, N; Sieniawski, M; Staak, O | 1 |
| Abboud, CN; Felgar, R; Komrokji, RS; Oliva, JL; Zand, M | 1 |
| Belford, D; Gates, P; Jablonskis, L; Januszewicz, H; Lillie, K; Prince, HM; Regester, G; Seymour, JF; West, R; Wolf, M | 1 |
| Arnaud, P; Bocaccio, C; Bourhis, JH; Carde, P; Ferme, C; Jabbour, E; Koscielny, S; Peslin, N; Ribrag, V; Vantelon, JM | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Bakshi, A; Bhagwat, R; Biswas, G; Khadwal, A; Narayanan, P; Parikh, P; Sastry, P | 1 |
| Antonenas, V; Bradstock, K; Collins, D; Crowther, H; Gottlieb, D; Kerridge, I; McGurgan, M | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Bauchmüller, K; Engelhardt, M; Finke, J; Haas, PS; Ihorst, G; Kühnemund, A | 1 |
| Brambilla, G; Castagna, L; Magagnoli, M; Masci, G; Morenghi, E; Pedicini, V; Poretti, D; Santoro, A | 1 |
| Bahlis, N; Balogh, A; Brown, C; Jones, A; Morris, DG; Russell, JA; Savoie, L; Stewart, DA; Valentine, K | 1 |
| Bystrická, E; Koza, V; Misaniová, L; Pavlicová, V; Scudlová, J; Valentová, D; Visokaiová, M; Vokurka, S | 1 |
| Gisselbrecht, C; Hagberg, H | 1 |
| Goh, YT; Hwang, WY; Koh, BC; Koh, LP; Linn, YC; Loh, SM; Ratnagopal, P; Tan, HC | 1 |
| Horvath, N; Keefe, D; Lees, J | 1 |
| Atkins, H; Bence-Bruckler, I; Bredeson, C; Huebsch, L; Leger, C; McDiarmid, S; Sabloff, M; Zhang, H | 1 |
| Caballero, D; Canales, MA; Hernandez-Navarro, F; Martin, A | 1 |
| Blechschmidt, M; Bornhäuser, M; Ehninger, G; Hänel, M; Hölig, K; Kroschinsky, F; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Poppe-Thiede, K; Schaich, M | 1 |
| Aldouri, M; Devereux, S; Milojković, D; Mufti, GJ; Pagliuca, A | 1 |
| Cupelli, L; de la Rubia, J; Jarque, I; Jiménez, C; Lorenzo, I; Martín, G; Martínez, JA; Puig, N; Remigia, MJ; Sanz, GF; Sanz, J; Sanz, MA | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Dong, HQ; Ji, BX; Lu, CY; Lu, DP; Su, L; Wan, SG; Xu, J; Yu, YY | 1 |
| Azzam, K; Hasmann, M; Nüssler, V; Pelka-Fleischer, R; Pogrebniak, A; Schemainda, I | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Bishton, MJ; Haynes, AP | 1 |
| Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M | 1 |
| Cağirgan, S; Ergene, U; Pehlivan, M; Tombuloğlu, M; Yilmaz, M | 1 |
| Bühlmann, M; Bükki, J; Ernst, S; Stanga, Z; Stucki, A | 1 |
| Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Atta, J; Chow, KU; Hoelzer, D; Martin, H; Mitrou, PS; Weidmann, E | 1 |
| Huijgens, PC; Keijzer, A; van de Loosdrecht, AA | 1 |
| Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A | 1 |
| Avigdor, A; Ben-Bassat, I; Hardan, I; Nagler, A; Oksman, Y; Shem-Tov, N; Shimoni, A; Yerushalmi, R; Zwas, ST | 1 |
| Abdelkefi, A; Ben Abdeladhim, A; Ben Othman, T; Ladeb, S; Lakhal, A; Torjman, L | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Lin, XB; Peng, YL; Wang, BF | 1 |
| Blundell, E; Goldstone, AH; Linch, DC; Peggs, KS; Thomson, KJ | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Ishizawa, K | 1 |
| Boccadoro, M; Bregni, M; Cabras, A; Calvi, R; Caracciolo, D; Comino, A; Corradini, P; Devizzi, L; Di Nicola, M; Fornari, A; Gallamini, A; Gianni, AM; Ladetto, M; Magni, M; Majolino, I; Mirto, S; Novero, D; Patti, C; Pescarollo, A; Ponzoni, M; Remotti, D; Rosato, R; Stella, M; Tarella, C; Zanni, M; Zoli, V | 1 |
| Abdelsalam, M; Akhtar, S; El Weshi, A; Hussaini, H; Janabi, I; Maghfoor, I; Rahal, M | 1 |
| Huh, J; Jang, G; Jo, JC; Kang, BW; Kim, JW; Kim, S; Koo, JE; Lee, SS; Suh, C; Sym, SJ | 1 |
| Al-Ali, HK; Niederwieser, D; Wittekind, C | 1 |
| Brand, R; Dreger, P; Michallet, M | 1 |
| Bauchmüller, K; Engelhardt, M; Ihorst, G; Strobel, ES | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
| Albo, C; Alonso, N; Arranz, R; Caballero, D; Conde, E; Fernández-Rañada, JM; Gandarillas, M; García Vela, JA; Garzón, S; Grande, C; Hernández, MT; Lahuerta, JJ; Mateos, MV; Rodríguez, J | 1 |
| Caballero, D; Canals, C; Finke, J; Goldstone, A; Hunter, A; Kienast, J; Kobbe, G; Kolb, HJ; Kyriakou, C; Metzner, B; Oberg, G; Reimer, P; Schmitz, N; Sureda, A; Theorin, N | 1 |
| Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S | 1 |
| Briones, J; Camós, M; Colomo, L; Escoda, L; Espinosa, I; Estany, C; Gutiérrez-García, G; López-Guillermo, A; Martínez, S; Martino, R; Mercadal, S; Montserrat, E; Pedro, C; Ribera, JM; Xicoy, B | 1 |
| Barada, WM; Bazarbachi, A; Beydoun, A; Hourani, R; Masroujeh, R; Otrock, ZK | 1 |
| Byrne, JL; Das-Gupta, EP; Devereux, S; Gonzalez, J; Haynes, AP; Ho, A; Ingram, W; McMillan, A; Mufti, GJ; Pagliuca, A; Russell, NH; Shaw, BE | 1 |
| Barbui, T; Benedetti, F; Boccadoro, M; Ciceri, F; Corradini, P; Cortelazzo, S; Gallamini, A; Gianni, AM; Magni, M; Majolino, I; Mirto, S; Passera, R; Patti, C; Pileri, A; Pizzolo, G; Rambaldi, A; Tarella, C; Zanni, M | 1 |
| Augustin, KM; Devine, SM; Dipersio, JF; Sempek, D; Vij, R; Wildes, TM; Zhang, QJ | 1 |
| Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Giannopoulou, V; Girkas, K; Ioannidou, E; Kalli, T; Ladas, SD; Papageorgiou, E; Papaxoinis, G; Pappa, V; Triantafyllou, K; Tsirigotis, P | 1 |
| Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF | 1 |
| Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S | 1 |
| Alinari, L; Baccarani, M; Derenzini, E; Fanti, S; Gandolfi, L; Musuraca, G; Stefoni, V; Tani, M; Venturini, F; Zinzani, PL | 1 |
| SEASHORE, HG | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Cook, G; Crawley, C; Fields, P; Hickling, R; Hunter, A; Mahendra, P; Marcus, R; Peniket, A; Wilson, K | 1 |
| Brault, P; Decaudin, D; Escande, MC; Girodet, J; Mariani, P; Mathiot, C; Precupanu, CM; Zanni, M | 1 |
| Hagiwara, S; Kawabata, KC; Miwa, A; Oka, S; Tachikawa, N; Takenouchi, A; Tanimura, A; Tanuma, J | 1 |
| Cooks, RG; Gao, L; Ouyang, Z; Smith, SA; Song, Q; Volný, M; Xu, W | 1 |
| Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M | 1 |
| Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Pintilie, M; Seshadri, T; Tsang, R; Zadeh, S | 1 |
| Adam, Z; Bolcák, K; Cerný, J; Fakan, F; Hájek, R; Krejcí, M; Kren, L; Mayer, J; Neubauer, J; Pour, L; Smardová, L; Soumarová, R; Vanícek, J; Veselý, K | 1 |
| Martin, R; Schippling, S | 1 |
| Batár, P; Kiss, A; Kovácsné Kovács, E; Rejto, L; Reményi, G; Sípos, T; Szarvas, M; Szász, R; Udvardy, M; Váróczy, L | 1 |
| Bahlis, N; Mansoor, A; Stewart, DA | 1 |
| Barreira, AA; Barros, GM; Barros, JC; Brum, DG; Burt, RK; Hamerschlak, N; Kutner, JM; Madeira, MI; Mastropietro, AP; Moraes, DA; Neto, JZ; Oliveira, EA; Oliveira, MC; Paes, AT; Pieroni, F; Porto, PP; Ribeiro, AA; Rodrigues, M; Santana, CL; Santos, AC; Simões, BP; Stracieri, AB; Tylberi, CP; Voltarelli, JC | 1 |
| Gu, B; Liu, Y; Qiu, H; Ruan, C; Shi, X; Sun, A; Tang, X; Wu, D; Xue, S; Zhou, H | 1 |
| Cerno, M; Damiani, D; Fanin, R; Geromin, A; Patriarca, F; Rinaldi, C; Skert, C; Sperotto, A; Stocchi, R; Tiribelli, M; Zaja, F | 1 |
| Cascavilla, N; Crescimanno, A; Di Bartolomeo, P; Di Renzo, N; Lanza, F; Marcacci, G; Musso, M; Perrone, T; Pinto, A; Scalone, R | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Kuruvilla, J | 1 |
| Barosi, G; Fanti, S; Gianni, AM; Martelli, M; Petrini, M; Tura, S; Vitolo, U; Zinzani, PL | 1 |
| Qiao, W; Wang, C; Wang, T; Xing, Y; Zhao, J | 1 |
| Hashimoto, C; Ishigatsubo, Y; Motomura, S; Takasaki, H; Takemura, S | 1 |
| Aureli, V; Balduino, G; Caniglia, M; Cometa, AM; Isacchi, G; Landi, F; Miele, MJ; Pinto, RM; Rana, I; Scerpa, MC; Zinno, F | 1 |
| Butler, JB; Cooke, A; Demers, A; Liu, HW; Nugent, Z; Rubinger, M; Schroeder, G; Seftel, MD; Szwajcer, D | 1 |
| Boesen, AM; Browett, P; Cunningham, D; Grigg, A; Hancock, B; Holte, H; Hoskin, P; Jack, A; Linch, DC; Maclennan, K; Qian, W; Smith, P; Trneny, M; Yung, L | 1 |
| Havrdová, E; Kemlink, D; Kobylka, P; Kovárová, I; Kozák, T; Krasulová, E; Lhotáková, P; Pohlreich, D; Trneny, M; Vacková, B | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Mandanas, R; McGaughey, D; Orloff, G; Rifkin, R; Spitzer, G; Zhan, F | 1 |
| Schneider, AE; Talmon, GA | 1 |
| Cornely, OA; Keulertz, C; Lövenich, H; Rüping, MJ; Söhngen, D; Vehreschild, JJ; Wieland, U | 1 |
| Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
| Basu, A; Fritzer-Szekeres, M; Giessrigl, B; Graser, G; Grusch, M; Jaeger, W; Jayaprakash, V; Krupitza, G; Lackner, A; Saiko, P; Sinha, BN; Szekeres, T | 1 |
| Dong, HQ; Ji, BX; Liu, CY; Liu, YO; Su, L; Sun, WL; Wan, SG; Xu, J; Zhang, P | 1 |
| BRAESTRUP, CB; SINGER, G; WYCKOFF, HO | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Buset, EM; Haile, SR; Honegger, H; Knuth, A; Mischo, A; Pestalozzi, BC; Petrausch, U; Renner, C; Samaras, P; Schanz, U; Siciliano, RD; Stahel, RA; Stenner-Liewen, F; Stussi, G | 1 |
| Barbagallo, I; Chiarenza, A; Conticello, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Romano, A; Stagno, F; Tibullo, D | 1 |
| Bockova, J; Brandejsova, R; Bystricka, E; Chvojkova, I; Mazur, E; Mjartanova, D; Scudlova, J; Streinerova, K; Vasilieva, E; Visokaiova, M; Vitkova, J; Vodickova, M; Vokurka, S; Vrabcova, M | 1 |
| Cai, JL; Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Tsai, NC | 1 |
| Glass, B; Griesinger, F; Hasenkamp, J; Hohloch, K; Lakhani, VJ; Meller, J; Riggert, J; Sahlmann, CO; Trümper, L; Wulf, G | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Yamazaki, R | 1 |
| Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H | 1 |
| Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G | 1 |
| Bartlett, NL; Cashen, AF; Foyil, KV; Grove, LE; Kennedy, DA | 1 |
| Shigematsu, A | 1 |
| Dib, M; Gagnadoux, F; Paris, A; Rousselet, MC; Tazi, A; Urban, T | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Barzał, J; Gawroński, K; Młot, B; Oborska, S; Rzepecki, P; Szczylik, C; Waśko-Grabowska, A | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Massey, C; Puig, N; Seshadri, T; Tsang, R; Villa, D | 1 |
| de Rooij, M; Huijgens, PC; Visser, OJ; Wondergem, MJ; Zijlstra, JM; Zweegman, S | 1 |
| Avigdor, A; Avivi, I; Levi, I; Nagler, A; Or, R; Patachenko, P; Rowe, JM; Shimoni, A; Yeshurun, M; Zwas, T | 1 |
| Bruno, A; Cantoni, F; Cupelli, L; Datturi, T; De Angelis, V; de Fabritiis, P; De Meis, I; Dentamaro, T; Niscola, P; Tendas, A | 1 |
| Briere, J; Bron, D; Cogliatti, S; Cuccuini, W; Gaulard, P; Gisselbrecht, C; Hirchaud, E; Houlgatte, R; Mounier, N; Rosenwald, A; Soulier, J; Sundstrom, C; Thieblemont, C; Voelker, HU; Ysebaert, L | 1 |
| Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K | 1 |
| Dehghani, M; Haghighinejad, H; Mohamadian, M; Nourani, H; Ramzi, M; Vojdani, R; Zakerinia, M | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Ma, X; Ren, C; Sheng, Z; Wang, B; Xia, B; Zhang, W | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Andersen, NS; Bentzen, H; Brown, P; Delabie, J; Ehinger, M; Elonen, E; Eriksson, M; Geisler, CH; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kuittinen, O; Laurell, A; Lauritzsen, GF; Nilsson-Ehle, H; Nordström, M; Pedersen, LB; Ralfkiaer, E; Räty, R; Sundström, C | 1 |
| Brice, P; Brousse, N; Casasnovas, O; Delarue, R; Delmer, A; Haioun, C; Hermine, O; Lefrere, F; Ribrag, V; Salles, G; Tilly, H; Van Hoof, A | 1 |
| Beuthien-Baumann, B; Bornhäuser, M; Ehninger, G; Kroschinsky, F; Middeke, JM; Ordemann, R; Platzbecker, U; Platzek, I; Stöhlmacher, J; van den Hoff, J; Zietz, C | 1 |
| Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M | 1 |
| Bruno Ventre, M; Caligaris-Cappio, F; Cattaneo, C; Di Nicola, M; Donadoni, G; Ferreri, AJ; Foppoli, M; Fumagalli, L; Govi, S; Mappa, S; Re, A; Rossi, G; Spina, M; Tirelli, U | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Enke, C; Hankins, J; Loberiza, FR; Vose, JM; Weisenburger, DD | 1 |
| Cooney, JP; Kruger, PC; Turner, JH | 1 |
| Anderson, D; Greaves, P; Gribben, JG; Lillington, D; Lister, TA; Matthews, J; Montoto, S | 1 |
| Atalla, A; Borges dos Santos, K; Hallack Neto, AE | 1 |
| Fukayama, M; Kurokawa, M; Nakamura, F; Takazawa, Y; Uni, M; Yoshimi, A | 1 |
| Casper, J; Gebauer, W; Köhne, CH; Kraemer, D; Metzner, B; Müller, TH; Pott, C; Rosien, B; Schumann-Binarsch, S; Thole, R | 1 |
| Ambinder, R; Ayala, E; Burns, LJ; Carter, S; Fenske, T; Fisher, R; Horowitz, M; Mineshi, S; Moskowitz, CH; Press, OW; Stadtmauer, EA; Tomblyn, M; Vose, JM | 1 |
| Berdel, WE; Demant, A; Evers, G; Kessler, T; Köhler, G; Krug, U; Kuhlmann, M; Mesters, R; Mikesch, JH; Mohr, M; Müller-Tidow, C; Pohlen, M; Schliemann, C; Schmidt, E; Thoennissen, GB; Thoennissen, NH; Wessling, J | 1 |
| Aslan, D; Cetin, M; Eroglu, C; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Mentes, S; Orhan, O; Sahin, C; Sivgin, S; Soyuer, S; Unal, A; Yildiz, OG | 1 |
| Bembnista, E; Czyz, A; Dytfeld, D; Gil, L; Kazmierczak, M; Komarnicki, M; Kozlowska-Skrzypczak, M; Lojko-Dankowska, A; Matuszak, M; Nowicki, A | 1 |
| Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; Whalen, V; William, BM | 1 |
| Czajczynska, A; Gramatzki, M; Günther, A; Humpe, A; Kneba, M; Nickelsen, M; Raff, T; Repp, R; Schrappe, M; Schrauder, A; Schub, N | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Blijlevens, NM; de Haan, AF; Donnelly, JP; Herbers, AH; van der Velden, WJ | 1 |
| Go, A; Guo, R; Parthasarathy, M; Rodriguez, T; Smith, S; Sobol, U; Stiff, P; Vimr, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
| Hsieh, CH; Hsieh, PY; Lin, SC; Shueng, PW; Tien, HJ; Wang, LY | 1 |
| Bernal, T; Briones, J; Caballero, D; Canales, MA; García-Marco, JA; González-Barca, E; Grande, C; Hernández, M; Jarque, I; López, D; Moraleda, JM; Novelli, S; Palmero, F; Panizo, C; Tomás, JF; Torres, A | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Boyce, TG; Burnette, BL; Jentoft, MA; Porrata, LF; Witzig, TE | 1 |
| Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY | 1 |
| Allen, MS; Armitage, JO; Bierman, PJ; Bociek, RG; Loberiza, FR; Vose, JM; William, BM | 1 |
| Ardeshna, KM; Bird, A; Goldstone, AH; Kothari, J; Lambert, J; Linch, DC; Morris, E; Peggs, KS; Thomson, KJ; Virchis, AE | 1 |
| Ambrosetti, A; Attolico, I; Barzan, A; Benedetti, F; Bergui, L; Billio, A; Carlo-Stella, C; Chiarenza, A; Devizzi, L; Di Nicola, M; Di Raimondo, F; Gianni, AM; Gueli, A; Guidetti, A; Intermesoli, T; Magni, M; Matteucci, P; Montanari, M; Mulè, A; Olivieri, A; Parvis, G; Patti, C; Rambaldi, A; Scimè, R; Tarella, C; Trentin, L; Valagussa, P; Viero, P; Viviani, S | 1 |
| Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J | 1 |
| Monteith, G; Parsons-Doherty, M; Poirier, VJ | 1 |
| Chihara, D; Chou, T; Hasegawa, Y; Henzan, H; Izutsu, K; Kaneko, H; Kato, K; Kondo, E; Mizuta, S; Sakai, R; Sakamaki, H; Sugahara, H; Suzuki, R; Suzumiya, J; Yokoyama, K | 1 |
| Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Bentzen, H; Bogsrud, TV; Brown, Pde N; Delabie, J; Ehinger, M; Elonen, E; Fagerli, UM; Frederiksen, H; Geisler, CH; Grønbæk, K; Hansen, PB; Jerkeman, M; Karjalainen-Lindsberg, ML; Kimby, E; Kolstad, A; Kostova-Aherdan, K; Laurell, A; Lauritzsen, GF; Lehmann, AK; Loft, A; Nilsson-Ehle, H; Pedersen, LB; Ralfkiaer, E; Räty, R; Schildt, J; Sundstrom, C | 1 |
| Auger-Quittet, S; Daures, JP; Duny, Y; Quittet, P | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Caballero, MD; Cabrero-Calvo, M; García-Sanz, R; Labrador, J; Mateos, MV; Pérez-López, E; Vázquez, L | 1 |
| Atalla, A; Costa, LJ; dos Santos, KB; Hallack-Neto, AE; Pereira, J | 1 |
| D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ | 1 |
| Imai, K; Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Hatakeyama, N; Hori, T; Igarashi, K; Mizue, N; Suzuki, N; Tsutsumi, H; Yamamoto, M | 1 |
| Arranz, R; Bargay, J; Bello, JL; Caballero, MD; Conde, E; Coronado, M; González-Barca, E; Grande, C; Hernández, MT; Marín-Niebla, A; Martín, A; Montes-Moreno, S; Panizo, C; Pardal, E; Pérez-Ceballos, E | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N | 1 |
| Bordessoule, D; Bouabdallah, R; Bouteloup, M; Briere, J; Casasnovas, RO; Ciappuccini, R; Delmer, A; Fermé, C; Fruchart, C; Ghesquières, H; Gisselbrecht, C; Morschhauser, F; Tilly, H; Van Den Neste, E; Ysebaert, L | 1 |
| Forman, SJ; Hasenkamp, J; Krishnan, AY; Mei, M; Nademanee, A; Palmer, JM; Raubitschek, A; Shimoni, A; Simpson, J; Tsai, NC; Wondergem, MJ | 1 |
| Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV | 1 |
| Biron, P; Bouabdallah, R; Boumendil, A; Cahn, JY; Colombat, P; Cook, G; Cordonnier, C; Dreger, P; El-Najjar, I; Ferrant, A; Finel, H; Gribben, J; Haynes, AP; Luan, JJ; Mohty, M; Montoto, S; Pfreundschuh, M; Sureda, A; Thomson, K; Tilly, H; Vernant, JP | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Nagai, H | 1 |
| Caballero, MD; Capria, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Gobbi, M; Gonella, R; Isidori, A; Loscocco, F; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Specchia, G; Stefani, PM; Visani, G | 1 |
| Cook, G; Fox, C; Johnson, P; Kirkland, K; McQuaker, G; Pagliuca, A; Pearce, R; Perry, J; Robinson, S; Russell, N; Truelove, E | 1 |
| Banat, A; Basara, N; Derigs, G; Flohr, T; Frickhofen, N; Gramatzki, M; Hess, G; Kirschey, S; Kolbe, K; Link, H; Meyer, RG; Peter, N; Schmitz, N; Schulz, A; Theobald, M; Weidmann, E; Wolf, HH | 1 |
| Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A | 1 |
| Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
| Banz, Y; Berger, MD; Branger, G; Klaeser, B; Mueller, BU; Novak, U; Pabst, T; Taleghani, BM | 1 |
| Asada, H; Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H | 1 |
| Abela, EM; Anagnostopoulos, A; Apostolou, C; Baliakas, P; Batsis, I; Douka, V; Iskas, M; Kaloyannidis, P; Karypidis, K; Konstantinou, V; Kouvatseas, G; Mallouri, D; Marvaki, A; Sakellari, I; Smias, C; Sotiropoulos, D; Yannaki, E | 1 |
| Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L | 1 |
| Adil, SN; Ali, N; Shaikh, MU | 1 |
| Caimi, PF; Campagnaro, EL; Cooper, BW; Creger, RJ; de Lima, M; Fox, R; Fu, P; Gerson, SL; Lazarus, HM; Reese-Koc, J; Silva Rondon, CH; William, BM | 1 |
| Abidi, MH; Ayash, L; Bhutani, D; Deol, A; Dyson, G; Jain, T; Kim, S; Lum, LG; Ratanatharathorn, V; Uberti, JP; Veeraputhiran, M | 1 |
| Ben-Haroush, A; Even-Or, E; Stein, J; Yahel, A; Yaniv, I | 1 |
| Altuntaş, F; Civriz Bozdağ, S; Durgun, G; Esbah, O; Kaya, A; Kayıkçı, Ö; Kocubaba, Ş; Şirinoğlu Demiriz, I; Tekgündüz, E; Tetik, A | 1 |
| Bachy, E; Casasnovas, O; Freyer, G; Guitton, J; Hénin, E; Ribrag, V; Salles, G; Sebban, C; Tilly, H; Tod, M; You, B | 1 |
| Brozova, J; Dobrovolny, J; Kozak, T; Novak, J; Novakova, L | 1 |
| Bonizzoni, E; Carella, AM; Cascavilla, N; Ciochetto, C; Crescimanno, A; Di Carlo, P; Di Nicola, M; Di Renzo, N; Donnarumma, D; Lanza, F; Marcacci, G; Matera, R; Mele, A; Merenda, A; Messina, G; Moscato, T; Musso, M; Orciuolo, E; Pastore, D; Pavone, V; Pinto, A; Santarone, S; Scalone, R; Scalzulli, PR; Vitolo, U | 1 |
| Amorim, S; Bouabdallah, R; Boumendil, A; Choquet, S; de Rosa, G; Delmer, A; Dreger, P; Faber, E; Facchini, L; Falzetti, F; Ferrara, F; Finel, H; Finke, J; Kobbe, G; Nicolas-Virelizier, E; Salles, G; Sayer, H; Scime, R; Sellner, L; Sureda, A; Vallisa, D; Yakoub-Agha, I; Zuffa, E | 1 |
| Gore, A; Gupta, A; Jain, R; Jeevangi, N; Kannan, S; Khattry, N; Nair, R; Saikia, T; Thippeswamy, R | 1 |
| Agresta, F; Ayton, R; Bennett, A; Bhattacharyya, P; Cooke, RE; Grigg, A; Lasica, M; Stern, C; Taylor, E | 1 |
| Chwieduk, A; Fidyk, W; Giebel, S; Głowala-Kosińska, M; Mitrus, I; Najda, J; Smagur, A | 1 |
| Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q | 1 |
| Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P | 1 |
| Afanasyev, B; Arcese, W; Bacigalupo, A; Beelen, D; Ciceri, F; Giebel, S; Gülbas, Z; Koc, Y; Labopin, M; Mohty, M; Nagler, A; Piemontese, S; Polge, E; Rubio, MT; Santarone, S; Savani, BN; Schmid, C; Tischer, J; Wu, D | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Boulahdour, H; Daguindau, E; Deconinck, E; Helias, P; Philippe, L; Puyraveau, M | 1 |
| Chapuy, B; Feller, AC; Hasenclever, D; Hohloch, K; Loeffler, M; Pfreundschuh, M; Schmitz, N; Trümper, L; Wulf, G; Zeynalova, S; Ziepert, M | 1 |
| Ardeshna, KM; Foley, M; Kothari, J; Lambert, J; Linch, DC; Mackenzie, S; Morris, E; Peggs, KS; Thomson, K; Virchis, AE | 1 |
| Christofides, A; Isidori, A; Visani, G | 1 |
| Liu, HB; Wang, W | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kako, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Ammari, S; Canova, C; Dercle, L; Deutsch, E; Levy, A; Marabelle, A; Mazeron, R; Michot, JM; Ribrag, V; Rose, S; Rubin, E; Soria, JC | 1 |
| Abboud, C; Cashen, AF; Ceriotti, C; DiPersio, J; Fletcher, T; Gao, F; Ghobadi, A; Stockerl-Goldstein, K; Vij, R | 1 |
| Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L | 1 |
| Gullbo, J; Haglund, C; Hassan, SB; Höglund, M; Larsson, R; Strese, S; Velander, E | 1 |
| Bachanova, V; Brunstein, CG; Fair, C; Lazaryan, A; McClune, B; Rogosheske, J; Shanley, R | 1 |
| Bhat, V; Khattry, N; Toshniwal, M; Vira, H | 1 |
| Bouabdallah, K; Cornillon, J; Damaj, G; Gastinne, T; Ghésquières, H; Gressin, R; Gyan, E; Ranchon, F; Salles, G; Vigouroux, S; Yakoub-Agha, I | 1 |
| Butcher, B; Chong, G; Cull, G; Fay, K; Filshie, R; Gandhi, MK; Gill, D; Grigg, A; Hahn, U; Hertzberg, M; Hicks, RJ; Ho, SJ; Hofman, MS; Johnston, A; Kannourakis, G; Lewis, ID; Milliken, S; Renwick, W; Seymour, JF; Taper, J; Trotman, J; Warburton, P; Watson, AM; Wirth, A | 1 |
| Iranshahi, M; Nasseri, MA; Taleghani, A | 1 |
| Amorim, S; Bachy, E; Bay, JO; Bento, L; Bonifazi, F; Bouabdallah, R; Boumendil, A; Ceballos, P; Crawley, C; Damaj, G; Dreger, P; Finel, H; Gribben, J; Guilhot, F; Haenel, A; Huynh, A; Johnson, R; Le Gouill, S; Malladi, R; McQuaker, G; Metzner, B; Monjanel, H; Montoto, S; Nicolas-Virelizier, E; Orchard, K; Pohlreich, D; Poiré, X; Rambaldi, A; Rossi, G; Russell, NH; Thomson, K; Tilly, H | 1 |
| Billett, AL; Dahmoush, HM; Grant, FD; LaCasce, AS; Lehmann, LE; Margossian, SP; Ozuah, NW | 1 |
| Elliott, J; Finotello, R | 1 |
| Cassaday, RD; Cowan, A; Ermoian, R; Gopal, AK; Graf, SA; Holmberg, LA; Press, OW; Shadman, M; Smith, SD; Stevenson, PA; Till, BG; Tseng, YD | 1 |
| Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K | 1 |
| Lavolé, J; Le Goff, M; Mallet, V; Oudjit, A; Sogni, P | 1 |
| Braziel, RM; Chansky, K; Chen, AI; Dunlap, JB; Fan, G; Gay, ND; Leonard, JT; Maziarz, RT; Okada, CY; Raess, PW; Stentz, A | 1 |
| Baars, JW; Brouwer, R; Chamuleau, MED; de Jong, D; de Wreede, LC; Demandt, AMP; Doorduijn, JK; Hardi, L; Kersten, MJ; Kluin, PM; Nijland, M; Oosten, LEM; Siemes, C; Smeekes, OS; Stevens, WBC; Thielen, FW; Uyl-de Groot, CA; van Imhoff, GW; Veelken, H | 1 |
| Ansuinelli, M; Canfora, M; Cantonetti, M; Capria, S; Caputo, MD; Di Rocco, A; Giannarelli, D; Gumenyuk, S; Marchesi, F; Mengarelli, A; Palombi, F; Papa, E; Pisani, F; Provenzano, I; Pupo, L; Renzi, D; Romano, A; Serrao, A; Spadea, A; Trisolini, SM | 1 |
| Akhtar, S; Elhassan, TAM; Elshenawy, MA; Maghfoor, I; Shahzad Rauf, M | 1 |
| Avni, B; Grisariu, S; Or, R; Shapira, MY | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Fornecker, LM; Guffroy, A; Korganow, AS; Martin, M; Meyer, A | 1 |
| Dünweber, A; Fridthjof, KS; Friis, LS; Gørløv, JS; Kampmann, P; Kjeldsen, L; Moser, C; Møller, T; Nexø, C; Nørskov, KH; Welinder, PC | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Billio, A; Borghero, C; Calimeri, T; Carli, G; Cascavilla, N; Centurioni, R; Chiusolo, P; Codeluppi, K; Fama, A; Fanin, R; Federici, I; Ferrero, S; Finotto, S; Gherlinzoni, F; Ghione, P; Giannoccaro, M; Lanza, F; Loseto, G; Marino, D; Matera, R; Mazzone, AM; Mosna, F; Olivieri, A; Olivieri, J; Orciuolo, E; Pelosini, M; Perali, G; Rattotti, S; Saraceni, F; Sgherza, N; Sica, S; Stefani, PM; Tisi, MC; Tomei, G; Zaja, F | 1 |
| Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C | 1 |
| Ando, K; Fukuhara, N; Gomyo, H; Hanamura, I; Hotta, T; Kobayashi, H; Kobayashi, N; Kumagai, K; Kurosawa, M; Maruyama, D; Matsuno, Y; Miyazaki, K; Morishima, Y; Nagai, H; Nakamura, S; Nosaka, K; Ogura, M; Ohmachi, K; Ohnishi, K; Ohyashiki, K; Sawada, K; Shimoyama, T; Takayama, N; Taniwaki, M; Tobinai, K; Tsukamoto, N; Tsukasaki, K; Uike, N; Usuki, K; Utsumi, T; Wakabayashi, M; Yakushijin, Y; Yamamoto, K | 1 |
| Abou Mourad, Y; Clissa, C; Connors, JM; Gerrie, AS; Guiducci, B; Isidori, A; Loscocco, F; Nantel, SH; Power, M; Sanford, D; Savage, KJ; Scott, DW; Sehn, LH; Song, K; Sutherland, H; Toze, C; Tsang, ES; Villa, D; Visani, G | 1 |
| Ali, H; Budde, E; Chen, R; Forman, SJ; Herrera, AF; Mei, M; Mokhtari, S; Nademanee, A; Nakamura, R; Popplewell, L; Salhotra, A; Sandhu, K; Stiller, T; Zain, J | 1 |
| Barnett, MH; Barnett, Y; Ford, CD; Hendrawan, K; Khoo, ML; Kyle, KA; Ma, DDF; Ma, KC; Massey, JC; Milliken, ST; Moore, JJ; Sutton, IJ; Zaunders, JJ; Zivadinov, R | 1 |
| Bando-Polaino, I; Cabezas-Camarero, S; de la Orden García, V; Díaz-Rubio, E; García-Barberán, V; Llovet García, P; Mediero-Valeros, B; Merino Menéndez, S; Pérez-Segura, P; Subhi-Issa, AI | 1 |
| Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X | 1 |
| Amores-Fuster, I; Blackwood, L; Elliott, J; Finotello, R; Grant, IA; Harper, A; Killick, DR; Marrington, M; Mas, A; Smallwood, K; Tanis, JB | 1 |
| Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 2 |
| Arcani, R; Colle, J; Costello, RT; Fanciullino, R; Farnault, L; Ivanov, V; Jourde-Chiche, N; Mercier, C; Pourroy, B; Roche, P; Venton, G | 1 |
| Bishton, M; Campbell, R; Cheah, CY; Cochrane, T; De Mel Widanalage, S; Gilbertson, M; Hapgood, G; Hawkes, E; Hill, K; Johnston, A; Lee, HP; Manos, K; Nelson, N; Ng, M; Ng, ZY; Opat, S; Poon, M; Purtill, D; Ratnasingam, S; Ritchie, D; Schwarer, A; Seymour, J; Shorten, S; Sunny, T; Tam, C; Xin, L | 1 |
| Alexis, M; Amorim, S; Bay, JO; Chauchet, A; Chrétien, ML; Cluzeau, T; Contentin, N; Cornillon, J; Daguenet, E; de Latour, RP; Dorvaux, V; Gyan, E; Himberlin, C; Huynh, A; Lejeune, C; Mercier, M; Nicolas-Virelizier, E; Salles, G; Vallet, N | 1 |
| Hagiwara, S; Ishiyama, M; Izuka, Y; Kazama, H; Osanai, S; Ryuzaki, M; Shinohara, A; Shiseki, M; Tanaka, J; Tanaka, N; Watanabe, A; Yoshinaga, K | 1 |
| Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kebriaei, P; Lee, HC; Manasanch, EE; Mukherjee, A; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, RD; Popat, U; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM | 1 |
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Bañuelos-Ávila, AJ; Barrera-Chairez, E; Fernandez-Vargas, OE; Ron-Guerrero, CS; Ron-Magaña, AL | 1 |
| Hagiwara, S; Nagai, H; Okada, S; Saito, AM; Uehira, T | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Abraham, J; Borel, C; Bouabdallah, K; Bouabdallah, R; Casasnovas, RO; Chantepie, S; Damaj, G; Delapierre, B; Delette, C; Durot, E; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Gyan, E; Houot, R; Hueso, T; Ibrahim, A; Le Gouill, S; Lemal, R; Malak, S; Morello, R; Peyrade, F; Tchernonog, E; Tessoulin, B; Tournilhac, O | 1 |
| Ahmed, S; Ahn, KW; Aljurf, M; Bacher, U; Badawy, SM; Bejanyan, N; Cairo, M; Cerny, J; Epperla, N; Farhadfar, N; Fenske, TS; Freytes, CO; Gale, RP; Hamadani, M; Haverkos, B; He, Y; Hossain, N; Inwards, D; Jagadeesh, D; Kamble, RT; Kenkre, VP; Kharfan-Dabaja, MA; Lazarus, HM; Lazaryan, A; Lekakis, L; Litovich, C; Majhail, NS; Mei, M; Murthy, HS; Mussetti, A; Nathan, S; Nishihori, T; Olsson, RF; Ramakrishnan Geethakumari, P; Savani, BN; Sureda, A; Yared, JA | 1 |
| Deguchi, T; Kato, M; Kiyotani, C; Matsumoto, K; Mizuno, T; Nakadate, H; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yoshimura, S | 1 |
| Böhmer, LH; Chitu, DA; de Jong, D; de Jongh, E; de Weerdt, O; Doorduijn, JK; Hoogendoorn, M; Kersten, MJ; Kibbelaar, RE; Kluin-Nelemans, HC; Leys, RBL; Lugtenburg, PJ; MacKenzie, MA; Minnema, MC; Snijders, TJF; van Gelder, M; van Marwijk Kooij, R; Van't Veer, MB; Zijlstra, JM | 1 |
| Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A | 1 |
| Charifa, A; Ko, CJ; Lee, A; Levy, L; McNiff, JM; Paulson, N; Perincheri, S | 1 |
| Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS | 1 |
| Ballotta, L; Capria, S; Celentano, M; Ferrara, F; Marchesi, F; Mengarelli, A; Papa, E; Pedata, M; Picardi, A; Regazzo, G; Riccardi, C; Riemma, C; Terrenato, I; Trisolini, S | 1 |
| Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Kelsey, P; Kirkland, K; Lambert, J; Malladi, R; Morley, N; Paul, R; Pearce, R; Peniket, A; Perry, J; Snowden, JA | 1 |
| Allione, B; Calimeri, T; Cattaneo, C; Donadoni, G; Facchetti, F; Ferrari, D; Ferreri, AJM; Foppoli, M; Fumagalli, L; Lleshi, A; Pecciarini, L; Ponzoni, M; Re, A; Rigacci, L; Rossi, G; Sassone, M; Spina, M; Verga, L | 1 |
| Cartron, G; Casasnovas, O; Dalban, C; Ghesquières, H; Hernandez, C; Jardin, F; Le Bras, F; Le Gouill, S; Metzger, S; Nicolas-Virelizier, E; Pérol, D; Vizoso, S | 1 |
| Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I | 1 |
| Boudreault, JS; Desjardins, A; Feng, X; Le-Nguyen, V; Rioux, JP; Turgeon-Mallette, L; Veilleux, A; Vo, C | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| Birkmann, J; Blaudszun, AR; Bornhäuser, M; Ehninger, G; Fiedler, F; Fricke, S; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Kürzel, S; Schaefer-Eckart, K; Stahl, L | 1 |
| Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J | 1 |
| Ashkenazi, M; Avni, B; Grisariu, S; Lebel, E; Stepensky, P; Vainstein, V; Zimran, E | 1 |
| Bhar, S; Carrum, G; Craddock, J; Doherty, EE; Friend, BD; Heslop, HE; Hill, LC; John, TD; Kamble, RT; Krance, RA; Lulla, P; Martinez, C; Muhsen, IN; Patel, S; Pingali, SR; Ramos, CA; Salem, B; Sasa, G; Wang, T; Wu, M | 1 |
| Bouabdallah, K; Casasnovas, RO; Costes-Tertrais, D; Damaj, G; Dartigeas, C; Delette, C; Fogarty, P; Fornecker, LM; Garciaz, S; Gastinne, T; Gressin, R; Houot, R; Hueso, T; Le Gouill, S; Malak, S; Oberic, L; Ribrag, V; Tchernonog, E; Thieblemont, C | 1 |
| Chen, X; Chu, J; Huang, H; Jiang, Y; Jin, Z; Li, C; Liu, S; Qian, C; Qu, C; Wu, D; Xu, T; Yang, H; Zhang, L; Zhang, X; Zhou, J; Zhu, Q | 1 |
| Bashey, A; Brown, S; Holland, HK; Jackson, KC; Morris, LE; Shegda, N; Solh, M; Solomon, SR; Zhang, X | 1 |
| Chen, JB; Liu, L; Tang, XQ; Wang, J; Wang, L; Wang, X; Xiong, YY; Zhang, HB | 1 |
| Ghraichy, M; Jelcic, I; Martin, R; Müller, AM; Ruder, J; Schanz, U; Trück, J; von Niederhäusern, V | 1 |
| Ahmad, I; Bambace, N; Bernard, L; Boisjoly, JA; Bouchard, P; Bourguignon, A; Chagnon, M; Cohen, S; Delisle, JS; Fleury, I; Kiss, T; Lachance, S; Mollica, L; Roy, DC; Roy, J; Sauvageau, G; Veilleux, O; Zehr, J | 1 |
| Avni, B; Cohen, YI; Grisariu, S; Lebel, E; Shaulov, A; Stepensky, P; Zimran, E | 1 |
| Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R | 1 |
43 review(s) available for cytarabine and melphalan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Melphalan: Recent insights on synthetic, analytical and medicinal aspects.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Humans; Melphalan; Multiple Myeloma; Prodrugs; Structure-Activity Relationship | 2022 |
The treatment of plasma cell myeloma.
Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Melphalan; Methotrexate; Mice; Mice, Inbred BALB C; Multiple Myeloma; Myeloma Proteins; Prednisone; Procarbazine; Remission, Spontaneous | 1976 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
[Role of bone marrow graft in the treatment of acute lymphoblastic leukemias in children].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Reaction; HLA Antigens; Humans; Infant; Male; Melphalan; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Transplantation, Homologous | 1992 |
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 1991 |
What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Melphalan; Neutropenia; Pilot Projects; Randomized Controlled Trials as Topic; Registries; Time Factors; Transplantation, Autologous | 1991 |
Drug level monitoring: cytostatics.
Topics: Alkylating Agents; Aminoacridines; Amsacrine; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bleomycin; Busulfan; Chlorambucil; Chromatography, Gas; Chromatography, Liquid; Cisplatin; Cyclophosphamide; Cytarabine; Fluorouracil; Humans; Mass Spectrometry; Melphalan; Methotrexate; Mitomycins; Monitoring, Physiologic; Nitrosourea Compounds; Podophyllotoxin; Purines; Thiotepa; Vinca Alkaloids | 1985 |
Intracavitary chemotherapy.
Topics: Absorption; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Bacterial Infections; Bleomycin; Cisplatin; Cytarabine; Diffusion; Doxorubicin; Drug Synergism; Female; Fluorouracil; Humans; Immunotherapy; Melphalan; Methotrexate; Mitomycins; Neoplasms; Ovarian Neoplasms; Peritoneal Cavity; Permeability; Pleura; Pleural Effusion; Radiation-Sensitizing Agents; Sclerosis; Streptozocin | 1985 |
[Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy].
Topics: Anemia, Aplastic; Antineoplastic Agents; Colony-Stimulating Factors; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Neoplasms; Radiotherapy | 1989 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lomustine; Melphalan; Mitoxantrone | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Indications for and benefits of intensive therapies in treatment of childhood cancers.
Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Methotrexate; Neoplasms; Osteosarcoma; Risk; Sarcoma, Ewing | 1986 |
Intraperitoneal chemotherapy: a review.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Evaluation Studies as Topic; Fluorouracil; Humans; Injections, Intraperitoneal; Liver; Mathematics; Melphalan; Methotrexate; Peritoneum | 1986 |
[Ultrahigh-dosage cytostatics--their possible use in acute leukemias?].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Recurrence | 1987 |
[Principles of the effect of cytostatics].
Topics: Antineoplastic Agents; Asparaginase; Cell Division; Chlorambucil; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Fluorouracil; Folic Acid Antagonists; Humans; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Triaziquone; Triethylenephosphoramide; Vincristine | 1974 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclophosphamide; Cytarabine; Female; Fluorouracil; Humans; Leukemia L1210; Leukemia, Lymphoid; Lymphoma; Melphalan; Mercaptopurine; Methotrexate; Mice; Multiple Myeloma; Neoplasms; Nitrogen Mustard Compounds; Prednisone; Pregnancy; Time Factors; Trophoblastic Neoplasms; Vinblastine | 1971 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Hodgkin Disease; Humans; Hydroxyurea; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma; Melanoma; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Vincristine | 1973 |
[Burkitt's lymphoma and acute leukemias].
Topics: Acute Disease; Animals; Asparaginase; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Fluorouracil; Humans; Leukemia; Melphalan; Mercaptopurine; Methotrexate; Mice; Oncogenic Viruses; Prednisolone; Prednisone; Vincristine | 1969 |
Selective uptake and retention of anticancer agents by sensitive cells.
Topics: Animals; Antineoplastic Agents; Cytarabine; Doxorubicin; Floxuridine; Fluorouracil; Humans; Melphalan; Methotrexate; Neoplasms | 1980 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Digestive System Diseases; Etoposide; Heart Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung Diseases; Melphalan; Multicenter Studies as Topic; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
[Progress in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Interferon-alpha; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Vincristine | 1997 |
Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Melphalan; Middle Aged; Paraproteins; Remission Induction; Treatment Outcome; Vincristine | 1997 |
Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Encephalitis; Etoposide; Female; Humans; Immunoglobulins, Intravenous; Immunosuppression Therapy; Injections, Spinal; Interferon-alpha; Interleukin-12; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Melphalan; Memory Disorders; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1999 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
[Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Echocardiography, Transesophageal; Etoposide; Heart Failure; Heart Neoplasms; Heart Septum; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Immunocompetence; Injections, Spinal; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Middle Aged; Pleural Effusion; Prednisone; Remission Induction; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2002 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Finland; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Life Tables; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prednisone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Melphalan; Neoplasm, Residual; Neoplasms, Second Primary; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2007 |
Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prognosis; Risk Factors; Stomatitis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cytarabine; Dendritic Cell Sarcoma, Interdigitating; Drug Resistance, Neoplasm; Etoposide; Humans; Leg; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Soft Tissue Neoplasms; Tibia; Tomography, X-Ray Computed | 2009 |
[Stem cell therapy in multiple sclerosis: a clinical update].
Topics: Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carmustine; Central Nervous System; Clinical Trials, Phase II as Topic; Controlled Clinical Trials as Topic; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Melphalan; Mitoxantrone; Multicenter Studies as Topic; Multiple Sclerosis; Podophyllotoxin; Risk Assessment; Survival Rate; Treatment Outcome | 2009 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
[Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].
Topics: Acute Disease; Cyclophosphamide; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Recurrence; Risk; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning | 2014 |
Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Cytarabine; Disease-Free Survival; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Radiopharmaceuticals; Treatment Outcome | 2014 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine | 2014 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2016 |
Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin | 2017 |
[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 2018 |
155 trial(s) available for cytarabine and melphalan
| Article | Year |
|---|---|
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Recombinant Proteins; Recurrence; Transplantation, Autologous | 1992 |
BEAM autografting in lymphoma--experience at one centre.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Rate; Transplantation, Autologous | 1992 |
Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Whole-Body Irradiation | 1992 |
GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic System; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation, Autologous | 1991 |
The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Humans; Melphalan; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1991 |
Intracavitary chemotherapy.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Catheters, Indwelling; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunotherapy; Infusions, Parenteral; Melphalan; Methotrexate; Mitomycins; Mitoxantrone; Neoplasms; Organoplatinum Compounds | 1986 |
GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Granulocytes; Hodgkin Disease; Humans; Leukocyte Count; Macrophages; Melphalan; Neutropenia; Neutrophils; Postoperative Complications; Recombinant Proteins; Transplantation, Autologous | 1989 |
Overview of the clinical relevance of autologous bone marrow transplantation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous | 1986 |
Intraperitoneal chemotherapy: a review.
Topics: Abdominal Neoplasms; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Evaluation Studies as Topic; Fluorouracil; Humans; Injections, Intraperitoneal; Liver; Mathematics; Melphalan; Methotrexate; Peritoneum | 1986 |
Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Platelet Count | 1995 |
Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Fever; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Neutropenia; Retrospective Studies; Salvage Therapy | 1995 |
Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Base Sequence; Biomarkers, Tumor; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Child; Child, Preschool; Complement System Proteins; Cyclophosphamide; Cytarabine; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Male; Melphalan; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Neoplastic Stem Cells; Philadelphia Chromosome; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1993 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Confidence Intervals; Critical Care; Cytarabine; Erythrocyte Transfusion; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neutropenia; Platelet Transfusion; Podophyllotoxin; Preoperative Care; Prognosis; Recurrence; Salvage Therapy; Time Factors | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 1995 |
Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan.
Topics: Adult; Blood Transfusion, Autologous; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Transplantation, Autologous | 1994 |
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Methotrexate; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Survival Rate | 1993 |
Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome | 1994 |
Effects of bone marrow transplantation on myocardial function in children.
Topics: Adolescent; Adult; Blood Pressure; Bone Marrow Transplantation; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Echocardiography; Female; Heart; Humans; Infant; Leukemia, Myeloid, Acute; Male; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radionuclide Angiography; Time Factors; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Vincristine | 1993 |
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Risk; Survival Rate; Transplantation, Autologous | 1993 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged | 1995 |
Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1995 |
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Melphalan; Platelet Transfusion; Podophyllotoxin; Prospective Studies; Recombinant Proteins; Survival Analysis; Time Factors; Transplantation, Autologous | 1996 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome | 1996 |
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning | 1996 |
Factors for rapid and sustained hematopoietic reconstitution by circulating progenitor-cell transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis | 1996 |
Peripheral blood progenitor cell mobilization with Dexa-Beam/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cell Movement; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Lymphoma; Melphalan; Middle Aged; Phospholipid Ethers; Risk Factors; Transplantation Conditioning | 1996 |
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Neutropenia; Patient Selection; Recombinant Proteins; Thiotepa | 1997 |
Impact of high-dose salvage therapy (BEAM) on overall survival in younger patients with advanced large-cell lymphomas entered into BNLI trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Prednisone; Salvage Therapy; Treatment Outcome; Vincristine | 1997 |
Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Prospective Studies; Transplantation, Autologous | 1997 |
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Risk Factors | 1997 |
Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Whole-Body Irradiation | 1997 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation | 1998 |
Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Treatment of patients with malignant lymphoma with Mini-BEAM reduces the yield of CD34+ peripheral blood stem cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan | 1998 |
Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methotrexate; Methylprednisolone; Middle Aged; Mitomycins; Prednisone; Prospective Studies; Treatment Outcome; Vincristine | 1998 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine | 1998 |
Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy:
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Central Nervous System Neoplasms; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Male; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Testicular Neoplasms; Transplantation, Homologous; Whole-Body Irradiation | 1998 |
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Treatment Outcome; Vincristine | 1999 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug Resistance, Multiple; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors | 1999 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1999 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Rate; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carmustine; CD4-CD8 Ratio; Cytarabine; Etoposide; Female; Fever; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infections; Leukapheresis; Lymphocyte Subsets; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis; Neutropenia; Prognosis; Severity of Illness Index | 2000 |
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2000 |
Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Survival Rate; Transplantation, Autologous | 2000 |
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Idarubicin; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Melphalan; Pilot Projects; Transplantation Conditioning; Vidarabine | 2000 |
Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cyclosporine; Cytarabine; Etoposide; Female; Graft vs Tumor Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Pilot Projects; Risk Factors; Survival Rate; Transplantation Chimera; Vidarabine | 2000 |
Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granisetron; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lymphoma; Male; Melphalan; Nausea; Ondansetron; Serotonin Antagonists; Transplantation, Autologous; Tropisetron; Vomiting | 2000 |
A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Prospective Studies; Treatment Outcome | 2000 |
Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Depletion; Magnetic Resonance Imaging; Melphalan; Middle Aged; Multiple Sclerosis; Patient Selection; T-Lymphocytes | 2001 |
Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hodgkin Disease; Humans; Leukocyte Count; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Staging; Treatment Outcome | 2001 |
Risk-oriented postremission strategies in adult acute lymphoblastic leukemia: prospective confirmation of anthracycline activity in standard-risk class and role of hematopoietic stem cell transplants in high-risk groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Melphalan; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Gadolinium; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Preoperative Care; Transplantation, Autologous; Treatment Outcome | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoguazone; Recurrence; Salvage Therapy; Transplantation, Autologous; Vinblastine; Vinorelbine | 2002 |
The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prednisone; Prognosis; Survival Rate; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2000 |
Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Recombinant Proteins; Survival Rate; Treatment Outcome | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy | 2002 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Melphalan; Prognosis; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2002 |
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Germany; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisolone; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Risk; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
[Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
[Effectiveness of dose-intensive polychemotherapy with autologous hemopoietic cell transplantation for high-grade non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prednisone; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Survival Rate; Transplantation, Autologous | 2003 |
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2003 |
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Female; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine; Vindesine | 2004 |
Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2004 |
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytarabine; Female; Graft vs Host Disease; Humans; Immunophenotyping; Karyotyping; Male; Melphalan; Organophosphates; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2004 |
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Culture Techniques; Cells, Cultured; Cyclophosphamide; Cytarabine; Erythroid Precursor Cells; Humans; Integrin beta3; Lymphoma; Megakaryocytes; Melphalan; Peripheral Blood Stem Cell Transplantation; Platelet Membrane Glycoprotein IIb; Platelet Transfusion; Salvage Therapy; Thrombocytopenia; Thrombopoietin; Transplantation, Autologous; Treatment Outcome | 2004 |
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Radioimmunotherapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Treatment Outcome; Vincristine | 2005 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.
Topics: Adult; Aged; Anti-Infective Agents, Local; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mouth Mucosa; Mouthwashes; Peripheral Blood Stem Cell Transplantation; Povidone-Iodine; Sex Factors; Sodium Chloride; Stomatitis; Transplantation, Autologous | 2005 |
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2005 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Feasibility Studies; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Radiation-Protective Agents; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Vincristine | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Myeloablative Agonists; Podophyllotoxin; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2006 |
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care Facilities; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Eruptions; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Podophyllotoxin; Primary Prevention; Severity of Illness Index; South Australia; Stomatitis; Time Factors; Transplantation Conditioning; Treatment Outcome | 2006 |
Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2006 |
Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Male; Melphalan; Middle Aged; Morbidity; Mortality; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Celiac Disease; Combined Modality Therapy; Cytarabine; Enteral Nutrition; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gastrointestinal Diseases; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Sepsis; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2007 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Treatment Outcome | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous | 2008 |
Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2008 |
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Vincristine | 2008 |
Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mouthwashes; Phytohemagglutinins; Pilot Projects; Placebos; Recombinant Proteins; Stomatitis | 2009 |
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Radiotherapy Dosage; Salvage Therapy; Transplantation, Autologous | 2009 |
Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG.
Topics: Adult; Animals; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Rejection; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Horses; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Quality of Life; Rabbits; Transplantation Conditioning | 2010 |
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Feasibility Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Lymphoma; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Predictive Value of Tests; Prednisolone; Prednisone; Proportional Hazards Models; Radiopharmaceuticals; Rituximab; Teniposide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult | 2010 |
[Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Pulse Therapy, Drug; Rituximab; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vincristine; Young Adult | 2010 |
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Staging; Neutropenia; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Transplantation, Autologous; Young Adult | 2010 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuromyelitis Optica; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Spinal Cord; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryotherapy; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Prospective Studies; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Prospective Studies; Survival Rate; Transplantation, Autologous; Whole-Body Irradiation | 2011 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stem Cell Transplantation | 2011 |
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mouthwashes; Multiple Myeloma; Stomatitis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Odds Ratio; Prognosis; Proportional Hazards Models; Recurrence; Risk Factors; Sample Size; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Genes, myc; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Salvage Therapy; Transplantation, Autologous; Treatment Failure; Young Adult | 2012 |
Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cryopreservation; Cytarabine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Rituximab; Survival Rate; Transplantation, Autologous | 2012 |
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Kidney Diseases; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisone; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2013 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Melphalan; Middle Aged; Myeloablative Agonists; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Humans; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Radioimmunotherapy; Rituximab; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Transplantation, Autologous; Young Adult | 2013 |
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous | 2014 |
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Prospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine | 2014 |
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dactinomycin; Dexamethasone; Dog Diseases; Dogs; Female; Lymphoma; Male; Melphalan; Recurrence; Retrospective Studies | 2014 |
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm, Residual; Prognosis; Radioimmunotherapy; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prednisone; Prognosis; Prospective Studies; Radiopharmaceuticals; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prospective Studies; Risk Factors; Rituximab; Stem Cell Transplantation; Survival Rate | 2014 |
Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2014 |
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Nitrogen Mustard Compounds; Transplantation, Autologous | 2014 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Patient Selection; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Young Adult | 2015 |
Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Aged; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Podophyllotoxin; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2016 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult | 2016 |
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Myeloablative Agonists; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Obesity; Podophyllotoxin; Prospective Studies; Transplantation Conditioning | 2017 |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Positron-Emission Tomography; Prednisone; Retreatment; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2017 |
Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Child; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Positron-Emission Tomography; Preoperative Care; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2018 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting | 2018 |
R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Prednisone; Rituximab; Transplantation, Autologous; Vincristine; Young Adult | 2018 |
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Sirolimus; Survival Rate; Tacrolimus; Transplantation Conditioning | 2019 |
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Progression-Free Survival; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Autologous peripheral blood stem cell transplantation for relapsed/refractory HIV-associated lymphoma: a phase II clinical study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Feasibility Studies; Humans; Lymphoma, AIDS-Related; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Peripheral Blood Stem Cell Transplantation; Safety; Survival Rate; Transplantation, Autologous | 2020 |
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Netherlands; Prednisone; Progression-Free Survival; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Failure; Vincristine; Young Adult | 2020 |
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Survival Rate; Transplantation Conditioning | 2020 |
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Transplantation, Autologous | 2021 |
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Etoposide; Humans; Lymphoma, Follicular; Melphalan; Prospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy | 2022 |
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Topics: Bendamustine Hydrochloride; Cytarabine; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
366 other study(ies) available for cytarabine and melphalan
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Induction of morphological transformation in mouse C3H/10T1/2 clone 8 cells and chromosomal damage in hamster A(T1)C1-3 cells by cancer chemotherapeutic agents.
Topics: Antineoplastic Agents; Bleomycin; Carcinogens; Cell Transformation, Neoplastic; Cells, Cultured; Chromosomes; Cytarabine; Dactinomycin; Drug Evaluation, Preclinical; Hycanthone; Melphalan; Mercaptopurine; Methotrexate; Mutagens; Tilorone; Vincristine | 1977 |
Managing the complications of plasma cell myeloma.
Topics: Acute Kidney Injury; Bacterial Infections; Blood Urea Nitrogen; Blood Viscosity; Bone Neoplasms; Cephalothin; Cyclophosphamide; Cytarabine; Female; Fluoxymesterone; Furosemide; Gentamicins; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Neurologic Manifestations; Plicamycin; Renal Dialysis | 1975 |
Cytotoxicity studies of human melanoma cells and fibroblasts.
Topics: Animals; Cell Survival; Cells, Cultured; Cytarabine; Dacarbazine; DNA; DNA Repair; DNA, Neoplasm; Fibroblasts; Humans; Melanoma; Melphalan | 1979 |
[Effect of several chemotherapeutic agents on protein synthesis in leukemic plasma cells (author's transl)].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Cytarabine; Humans; Immunoglobulins; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Plasma Cells; Protein Biosynthesis; Vincristine | 1979 |
Early responses to chemotherapy detected by pulse cytophotometry.
Topics: Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Bone Marrow Cells; Cell Division; Child; Cytarabine; DNA, Neoplasm; Doxorubicin; Fluorometry; Humans; Leukemia; Lymphoma, Non-Hodgkin; Melphalan; Prednisone; Vincristine | 1976 |
Effect of cytostatic drugs on nucleic acid synthesis in mouse thymocytes and chick embryo cells.
Topics: Animals; Antineoplastic Agents; Cells, Cultured; Chick Embryo; Cytarabine; Dactinomycin; Deoxyadenosines; Deoxyuridine; DNA; Fluorouracil; Melphalan; Methotrexate; Mice; Mice, Inbred Strains; Thymidine; Thymus Gland; Triaziquone; Tritium; Uridine; Vinblastine | 1975 |
Mouse myeloma. A model for studies of cell kinetics.
Topics: Alkylating Agents; Animals; Bone Marrow; Bone Marrow Cells; Bone Neoplasms; Cell Division; Cells, Cultured; Cyclophosphamide; Cytarabine; Disease Models, Animal; Kinetics; Melphalan; Methotrexate; Mice; Mice, Inbred BALB C; Myeloma Proteins; Neoplasms, Experimental; Plasmacytoma; Thymidine; Tritium; Vinblastine; Vincristine | 1975 |
Schedule-dependent synergistic cytotoxicity of arabinofuranosylcytosine with adriamycin or 3,6-bis(5-chloro-2-piperidinyl)-2,5-piperazinedione in cultured cells.
Topics: Cell Division; Cells, Cultured; Cytarabine; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Melphalan; Piperazines; Piperidines | 1975 |
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphalan; Methotrexate; Stomach Neoplasms; Vinblastine | 1975 |
Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Salvage Therapy; Whole-Body Irradiation | 1992 |
BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia-Lymphoma, Adult T-Cell; Melphalan; Middle Aged | 1992 |
Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Risk Factors; Time Factors | 1992 |
[p170 in multiple myeloma and acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Colonic Neoplasms; Cytarabine; Daunorubicin; Drug Resistance; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Male; Melphalan; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Peptichemio; Plasma Cells; Prednisone; Remission Induction; Survival Rate; Tumor Cells, Cultured; Vincristine | 1991 |
High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dianhydrogalactitol; Doxorubicin; Female; Fluorouracil; Humans; Hydroxydopamines; Hydroxyurea; Infant; Male; Melphalan; Neoplasm Staging; Neuroblastoma; Oxidopamine; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Vincristine; Whole-Body Irradiation | 1991 |
Inhibition of DNA repair and the enhancement of cytotoxicity of alkylating agents.
Topics: Alkylating Agents; Antineoplastic Agents; Aphidicolin; Cell Line; Cell Survival; Cisplatin; Cytarabine; Diterpenes; DNA Damage; DNA Repair; Female; Humans; Lung Neoplasms; Melphalan; Nucleic Acid Synthesis Inhibitors; Ovarian Neoplasms; Thiotepa | 1991 |
BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies | 1990 |
Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Evaluation Studies as Topic; Hodgkin Disease; Humans; Male; Melphalan; Prednisone; Premedication; Remission Induction; Vincristine | 1990 |
[Kinetics of etoposide cytotoxicity against mouse P388 leukemia].
Topics: Animals; Bleomycin; Cell Cycle; Cell Survival; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Leukemia P388; Leukemia, Experimental; Melphalan; Mice; Peplomycin; Podophyllotoxin; Tumor Stem Cell Assay; Vinblastine | 1985 |
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate | 1986 |
[Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
Topics: Adult; Aged; Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neprilysin; Prednisolone; Prednisone; Prognosis; Vincristine | 1987 |
Recombinant human granulocyte-macrophage colony-stimulating factor plus the beam regimen instead of autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Stimulating Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Recombinant Proteins | 1989 |
Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance; Etoposide; Humans; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Vincristine | 1989 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematologic Diseases; Humans; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Thymoma; Thymus Neoplasms | 1988 |
The effect of pretreatment with thio-TEPA and cytosine arabinoside on megakaryocytopoiesis in rats given a sublethal dose of thio-TEPA.
Topics: Animals; Body Weight; Cytarabine; Hematopoiesis; Intestinal Mucosa; Male; Megakaryocytes; Melphalan; Rats; Rats, Inbred Lew; Species Specificity; Thiotepa; Time Factors | 1987 |
A comparative pathological study of liver injury after different combination chemotherapies for leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Liver; Melphalan; Prednisolone; Prednisone; Thioguanine | 1988 |
[Chemotherapeutic effects in hypoplastic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Cytarabine; Drug Evaluation; Humans; Immunoglobulin G; Immunotoxins; Infusions, Intravenous; Leukemia, Myeloid, Acute; Melphalan; Middle Aged; Preleukemia | 1988 |
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Podophyllotoxin | 1988 |
Comparison of the sensitivity of normal and leukaemic myeloid progenitors to in-vitro incubation with cytotoxic drugs: a study of pharmacological purging.
Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Cell Survival; Clone Cells; Cyclophosphamide; Cytarabine; Etoposide; Granulocytes; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Melphalan; Transplantation, Autologous; Tumor Cells, Cultured | 1987 |
Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Female; Hodgkin Disease; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin | 1986 |
In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration.
Topics: Anthraquinones; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Female; Fluorouracil; Humans; Infusions, Parenteral; Melphalan; Mitomycin; Mitomycins; Mitoxantrone; Ovarian Neoplasms; Peritoneal Cavity; Tumor Stem Cell Assay | 1985 |
Melphalan and cytarabine administered intraperitoneally as single agents and combination intraperitoneal chemotherapy with cisplatin and cytarabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Digestive System Neoplasms; Doxorubicin; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Melphalan; Middle Aged; Ovarian Neoplasms; Peritoneal Cavity | 1985 |
Experimental investigations on problems of the clinical use of L-asparaginase.
Topics: Animals; Antibody Formation; Antineoplastic Agents; Asparaginase; Cytarabine; Dactinomycin; Drug Resistance; Drug Synergism; Escherichia coli; Immunization; Immunosuppressive Agents; Leukemia, Experimental; Melphalan; Mice; Mice, Inbred Strains; Neoplasm Metastasis; Neoplasm Transplantation; Podophyllin; Procarbazine; Time Factors; Vincristine | 1970 |
Sideroblastic anemia in multiple myeloma: a preleukemic change.
Topics: Anemia, Sideroblastic; Bone Marrow Examination; Cytarabine; Female; Humans; Immunodiffusion; Immunoelectrophoresis; Immunoglobulins; Iron; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Melphalan; Mercaptopurine; Middle Aged; Multiple Myeloma; Muramidase; Precancerous Conditions; Prednisone; Staining and Labeling; Vincristine | 1973 |
Acute leukaemia in myeloma.
Topics: Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Mercaptopurine; Middle Aged; Multiple Myeloma | 1973 |
Plasma cell leukemia: detailed studies and response to therapy.
Topics: Acid Phosphatase; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Fluorescent Antibody Technique; Glucuronidase; Histocytochemistry; Humans; Immunoelectrophoresis; Immunoglobulin Fragments; Karyotyping; Leukemia, Plasma Cell; Male; Melphalan; Microscopy, Electron; Microscopy, Fluorescence; Middle Aged; Plasma Cells; Prednisone; Prognosis; Remission, Spontaneous; Staining and Labeling; Vincristine | 1974 |
Chemotherapy of metastatic malignant melanoma. Experience with 73 patients.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Colchicine; Cyclophosphamide; Cytarabine; Eye Neoplasms; Female; Floxuridine; Humans; Hydroxyurea; Idoxuridine; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Nitrogen Mustard Compounds; Nitrosourea Compounds; Skin Neoplasms; Vinblastine; Vincristine; Vulvar Neoplasms | 1971 |
Cell cycle phase specificity of antitumor agents.
Topics: Alkaloids; Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carbazoles; Cell Line; Chlorambucil; Cricetinae; Cytarabine; Dactinomycin; Depression, Chemical; DNA; Fibroblasts; Floxuridine; In Vitro Techniques; Lung; Melphalan; Mitosis; Neoplasms, Experimental; Nitrosourea Compounds; Nucleosides; Protein Biosynthesis; RNA; Streptozocin; Thiosemicarbazones | 1972 |
Acute leukemias and Burkitt's lymphoma. Present status of therapy.
Topics: Antineoplastic Agents; Asparaginase; Burkitt Lymphoma; Choriocarcinoma; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Female; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Melphalan; Mercaptopurine; Methotrexate; Prednisone; Pregnancy; Vincristine; Wilms Tumor | 1968 |
The combined effect of drugs and tumor-specific antibodies in protection against a mouse lymphoma.
Topics: Animals; Antibodies, Neoplasm; Chlorambucil; Cytarabine; Immune Sera; Immunotherapy; Lymphoma; Melphalan; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Rabbits; Time Factors | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytarabine; Daunorubicin; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Fluorouracil; Hodgkin Disease; Humans; Leukemia; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Male; Mechlorethamine; Melphalan; Mice; Mice, Inbred AKR; Multiple Myeloma; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Vinblastine; Vincristine | 1974 |
A case of acute myelomonocytic leukaemia associated with myelomatosis.
Topics: Aged; Autopsy; Blood Cell Count; Blood Protein Disorders; Blood Protein Electrophoresis; Bone Marrow; Bone Marrow Cells; Cytarabine; Daunorubicin; Humans; Immunoelectrophoresis; Immunoglobulin G; Leukemia, Myeloid; Male; Melphalan; Multiple Myeloma; Prednisone | 1973 |
Approaches to combination chemotherapy in rat, mouse, and hamster tumors.
Topics: Adenocarcinoma; Amides; Androstanols; Animals; Antineoplastic Agents; Cricetinae; Cyclohexanes; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Estradiol; Female; Hydroxyurea; Imidazoles; Mammary Neoplasms, Experimental; Melanoma; Melphalan; Mice; Mice, Inbred C3H; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Osteosarcoma; Plasmacytoma; Progesterone; Rats; Sarcoma, Experimental; Triazenes | 1974 |
Primary amyloidosis and acute leukemia associated with melphalan therapy.
Topics: Amyloidosis; Blood Cell Count; Blood Platelets; Blood Transfusion; Bone Marrow Examination; Cephalothin; Cytarabine; Erythrocytes; Gentamicins; Hemoglobins; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Proteinuria; Thioguanine | 1974 |
An in vitro study of the effect of cytostatic drugs on DNA synthesis in methylcholanthrene induced mouse sarcomas and in rat Walker 256 tumours.
Topics: Animals; Carcinoma 256, Walker; Cytarabine; DNA, Neoplasm; Drug Resistance; Female; Male; Melphalan; Methylcholanthrene; Mice; Neoplasm Transplantation; Rats; Sarcoma, Experimental; Spectrophotometry; Transplantation, Homologous; Tritium; Vinblastine | 1973 |
On the presence within tumours of clones that differ in sensitivity to cytostatic drugs.
Topics: Animals; Clone Cells; Cytarabine; DNA, Neoplasm; Melphalan; Methylcholanthrene; Mice; Neoplasm Transplantation; Sarcoma, Experimental; Thymidine; Transplantation, Homologous; Tritium; Vinblastine | 1974 |
Cell clones with different sensitivity to cytostatic drugs in methylcholanthrene-induced mouse sarcomas.
Topics: Animals; Clone Cells; Cytarabine; DNA, Neoplasm; Female; Melphalan; Methylcholanthrene; Mice; Neoplasm Transplantation; Sarcoma, Experimental; Thymidine; Transplantation, Homologous; Tritium; Vinblastine | 1974 |
An in vitro study of cytostatic drug effect on the drug effect on the DNA synthesis in methylcholanthrene induced mouse sarcomas. Correlation between in vitro results and the response in vivo.
Topics: Animals; Cell Transformation, Neoplastic; Cytarabine; Depression, Chemical; DNA, Neoplasm; Drug Resistance; Female; In Vitro Techniques; Leukocyte Count; Melphalan; Methylcholanthrene; Mice; Neoplasm Transplantation; Sarcoma, Experimental; Stimulation, Chemical; Thymidine; Time Factors; Transplantation, Homologous; Tritium; Vinblastine | 1974 |
[Chemotherapy of cancer. Hints for continuing medical education].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Education, Medical, Continuing; Fluorouracil; Humans; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Procarbazine; Triaziquone; Vinblastine; Vincristine | 1974 |
Remission of leukemia associated with multiple myeloma.
Topics: Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Remission, Spontaneous | 1971 |
Leukaemia on myeloma.
Topics: Adult; Bronchopneumonia; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Thioguanine | 1971 |
Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival.
Topics: Adolescent; Antineoplastic Agents; Burkitt Lymphoma; Busulfan; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cytarabine; Female; Humans; Immunotherapy; Infant; Kenya; Male; Mannitol; Melphalan; Methotrexate; Nitrogen Mustard Compounds; Nitroso Compounds; Urea | 1967 |
Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Separation; Cell Survival; Cells, Cultured; Cisplatin; Cricetinae; Cricetulus; Cytarabine; Doxorubicin; Female; Hydroxyurea; Interphase; Melphalan; Mesylates; Metaphase; Ovary | 1980 |
Autologous marrow transplantation for patients with chronic myelogenous leukemia (CML) in blast crisis.
Topics: Adult; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Doxorubicin; Female; Freezing; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Teniposide; Thioguanine; Tissue Preservation; Transplantation, Autologous | 1984 |
Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Topics: Antineoplastic Agents; Cell Survival; Cytarabine; Dactinomycin; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Female; Fluorouracil; Half-Life; Humans; In Vitro Techniques; Melphalan; Methotrexate; Ovarian Neoplasms | 1980 |
On heterogeneity of non-Hodgkin's lymphomas as regards sensitivity to cytostatic drugs. An in vitro study.
Topics: Cells, Cultured; Cytarabine; DNA, Neoplasm; Humans; Lymphoma; Melphalan; Prednimustine; Thymidine; Vincristine | 1980 |
Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, AIDS-Related; Melphalan; Prednisolone; Vincristine | 1994 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa | 1995 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Glyoxal; Graft Survival; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multivariate Analysis; Prednimustine; Prednisolone; Prednisone; Procarbazine; Radiotherapy; Retrospective Studies; Salvage Therapy; Vinblastine; Vincristine | 1995 |
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Graft Rejection; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Follicular; Melphalan; Middle Aged; Pancytopenia; Podophyllotoxin; Prednisone; Prognosis; Teniposide; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marrow Transplantation; Busulfan; Carmustine; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Susceptibility; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Monocytes; Neopterin; Podophyllotoxin; Respiratory Burst; Superoxides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Whole-Body Irradiation | 1995 |
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma; Male; Melphalan; Middle Aged; Salvage Therapy; Time Factors | 1993 |
Induction of ovarian function by using short-term human menopausal gonadotrophin in patients with ovarian failure following cytotoxic chemotherapy for haematological malignancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Female; Follicle Stimulating Hormone; Hodgkin Disease; Humans; Leukemia, Myelomonocytic, Acute; Luteinizing Hormone; Melphalan; Menotropins; Ovulation Induction; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy, Multiple; Primary Ovarian Insufficiency; Remission Induction; Teniposide; Thioguanine; Vincristine | 1993 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cell Count; Combined Modality Therapy; Cytarabine; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Opportunistic Infections; Survival Analysis | 1995 |
Pregnancy after autologous bone marrow transplantation for malignant lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infant, Newborn; Lymphoma, Large B-Cell, Diffuse; Mechlorethamine; Melphalan; Podophyllotoxin; Prednisone; Pregnancy; Pregnancy Outcome; Procarbazine; Remission Induction; Salvage Therapy; Vincristine | 1994 |
Bone marrow transplantation in Iran.
Topics: Adolescent; Adult; Anemia, Aplastic; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Financing, Personal; Graft vs Host Disease; Humans; Insurance, Health, Reimbursement; Iran; Lymphoma; Male; Melphalan; Middle Aged; Transplantation, Autologous; Transplantation, Homologous | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Multiple Myeloma; Transplantation, Autologous; Whole-Body Irradiation | 1994 |
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Follicle Stimulating Hormone; Humans; Leydig Cells; Luteinizing Hormone; Lymphoma; Male; Melphalan; Spermatozoa; Transplantation, Autologous | 1994 |
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate | 1993 |
Relapse of aggressive myeloma after complete remission in secondary acute leukemia: coincidence or consequence?
Topics: Antigens, CD; Bone Marrow; Cytarabine; Female; HLA-DR Antigens; Humans; Leukemia, Myelomonocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence | 1993 |
Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Melphalan; Molecular Sequence Data; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1993 |
A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Lymphoma; Lymphoma, Non-Hodgkin; Macrophages; Male; Melphalan | 1995 |
Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion, Autologous; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Pilot Projects; Recombinant Proteins; Vincristine | 1996 |
The combination of melphalan, cyclophosphamide and cytosine arabinoside as a conditioning regimen for autologous bone marrow transplantation for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1996 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Successful mobilisation of blood stem cells following previous autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Lymphoma, Follicular; Male; Melphalan; Methotrexate; Podophyllotoxin; Prednisolone; Prednisone; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1996 |
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cold Temperature; Combined Modality Therapy; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin | 1996 |
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins | 1996 |
Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged | 1996 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine | 1997 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutrophils; Platelet Count; Transplantation Conditioning | 1997 |
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methylprednisolone; Middle Aged; Myeloproliferative Disorders; Neutropenia; Salvage Therapy; Survival Rate; Time Factors | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Child; Cytarabine; Female; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Length of Stay; Male; Melphalan; Podophyllotoxin; Recurrence; Treatment Outcome | 1997 |
Enhanced apoptosis in metallothionein null cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bleomycin; Cadmium; Cell Division; Cisplatin; Cytarabine; DNA Fragmentation; Melphalan; Metallothionein; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mutagens; Oxidants; Peroxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; tert-Butylhydroperoxide; Tumor Suppressor Protein p53; Zinc | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 1997 |
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Treatment Outcome | 1997 |
BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prednisone; Survival Rate; Treatment Outcome; Vincristine | 1997 |
[Autologous transplant with BEAM protocol in lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 1997 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Transplantation, Autologous | 1997 |
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow; Carmustine; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Treatment Failure | 1998 |
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Female; Heart; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lung; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Neutrophils; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Ventricular Function, Left | 1998 |
[Intensive treatment of T-cell-rich B lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; T-Lymphocyte Subsets; Vincristine | 1998 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoguazone; Salvage Therapy; Time Factors | 1998 |
Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Pilot Projects; Prednisone; Survival Rate; Transplantation, Autologous; Vincristine | 1998 |
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyps; Lymphoma, B-Cell; Male; Melphalan; Middle Aged; Prednisone; Transplantation, Autologous; Vincristine | 1998 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Remission Induction; Retrospective Studies | 1998 |
Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colony-Forming Units Assay; Cytarabine; Dexamethasone; Etoposide; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Lymphoma; Male; Melphalan; Middle Aged; Recombinant Proteins; Retrospective Studies | 1998 |
Clonal myelodysplastic cells present in apheresis product before transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 7; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma, B-Cell; Lymphoma, Follicular; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies | 1998 |
[The efficacy of polychemotherapy programs in treating multiple myeloma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Prednisone; Remission Induction; Vincristine | 1998 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Hungary; Leukemia; Melphalan; Podophyllotoxin; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1998 |
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Topics: Adult; Ambulatory Care; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies | 1999 |
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 1999 |
Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Leukemia, Plasma Cell; Male; Melphalan; Middle Aged; Remission Induction; Survivors; Treatment Outcome; Vincristine | 1999 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Chlorambucil; Cohort Studies; Combined Modality Therapy; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Incidence; Infant; Leukemia, Myeloid; Life Tables; Lomustine; Male; Mechlorethamine; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Podophyllotoxin; Prednisolone; Prednisone; Procarbazine; Retrospective Studies; Risk; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Hospital Costs; Hospital Units; Hospitalization; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Melphalan; Netherlands; Parenteral Nutrition; Patient Isolation; Podophyllotoxin; Prednisone; Retrospective Studies; Transplantation, Autologous; Vincristine | 1999 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Transplantation, Homologous | 2000 |
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Automation; Biomarkers; Carmustine; Cytarabine; Female; Flow Cytometry; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutrophils; Podophyllotoxin; Predictive Value of Tests; Reticulocyte Count; Reticulocytes; Time Factors; Transplantation, Autologous | 2000 |
Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Southern; Cell Division; Cytarabine; Cytidine Deaminase; DNA, Complementary; Drug Resistance, Neoplasm; Fibroblasts; Gene Transfer Techniques; Genetic Vectors; Glutathione Transferase; Humans; Mechlorethamine; Melphalan; Mice; Protein Biosynthesis; Rats; Retroviridae; Tetrazolium Salts; Thiazoles; Transduction, Genetic | 2000 |
Oxidative burst measurement in patients treated with cytostatics: influence of G-CSF and role as a prognostic factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Escherichia coli; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Prognosis; Respiratory Burst; Tetradecanoylphorbol Acetate | 2000 |
Expression of CD11b/CD18 on neutrophils after consolidation chemotherapy for acute myeloid leukemia and after high dose chemotherapy with autologous haematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; CD18 Antigens; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Macrophage-1 Antigen; Male; Melphalan; Middle Aged; Neoplasm Proteins; Neutropenia; Recombinant Proteins; Remission Induction | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; L-Lactate Dehydrogenase; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Transplantation, Autologous | 2000 |
Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Carmustine; Cell Lineage; Combined Modality Therapy; Cytarabine; Disease Susceptibility; Female; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphopenia; Male; Melphalan; Middle Aged; Podophyllotoxin; Sweden; Transplantation Conditioning; Transplantation, Autologous | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Male; Mediastinal Neoplasms; Melphalan; Middle Aged; Neoplasm, Residual; Prognosis; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy | 2000 |
Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Chemokine CCL4; Cisplatin; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Etoposide; Female; Growth Inhibitors; Hematopoietic Stem Cells; Macrophage Inflammatory Proteins; Melphalan; Mice; Mice, Inbred BALB C; Pentoxifylline; Spleen; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2000 |
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2000 |
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Topics: Adolescent; Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Time Factors; Transplantation Conditioning | 2000 |
Two-step immunoablative treatment with autologous peripheral blood CD34(+) cell transplantation in an 8-year-old boy with autoimmune haemolytic anaemia.
Topics: Anemia, Hemolytic, Autoimmune; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Plasmapheresis; Podophyllotoxin; Prednisolone; Splenectomy; Stem Cells; Transplantation, Autologous; Treatment Outcome | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine | 2000 |
Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cytarabine; Epoetin Alfa; Erythrocyte Transfusion; Erythropoietin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Lymphoma, Non-Hodgkin; Melphalan; Platelet Transfusion; Recombinant Proteins; Treatment Outcome | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carmustine; Cefotaxime; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Idarubicin; Immunocompromised Host; Immunosuppressive Agents; Levofloxacin; Lymphoma, T-Cell; Male; Melphalan; Ofloxacin; Penicillin Resistance; Pneumococcal Infections; Prednisone; Recurrence; Rifampin; Splenectomy; Streptococcus pneumoniae; Transplantation Conditioning; Vincristine | 2000 |
Characterization of DNA fragmentation events caused by genotoxic and non-genotoxic agents.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cytarabine; DNA; DNA Damage; DNA Fragmentation; Electrophoresis, Gel, Pulsed-Field; Enzyme Inhibitors; Etoposide; Formamides; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Melphalan; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
[Changes of thyroid and adrenocortical functions after bone marrow transplantation with MAC conditioning regimen in leukemia patients].
Topics: Adolescent; Adrenal Cortex; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Cytarabine; Female; Humans; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thyroid Gland; Transplantation Conditioning | 1998 |
[Outcome of autologous bone marrow transplantation in 73 patients with acute leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1998 |
Complete remission of generalized relapsed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type of the gastrointestinal tract after high-dose chemotherapy and autologous peripheral stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Melphalan; Middle Aged; Remission Induction; Transplantation, Autologous | 2000 |
[Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2000 |
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Recurrence; Salvage Therapy; Sex Factors; Survival Analysis; Transplantation, Autologous | 2001 |
Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cytarabine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; K562 Cells; Killer Cells, Natural; Lymphocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2001 |
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Infections; Male; Melphalan; Middle Aged; Neutropenia; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Safety; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Prognosis; Radiopharmaceuticals; Survival Analysis; Survival Rate; Tomography, Emission-Computed; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2002 |
Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Chromosomes, Human, Pair 3; Cyclophosphamide; Cytarabine; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Etoposide; Female; Genes, bcl-2; Humans; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Point Mutation; Prednisolone; Prednisone; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogenes; Transcription Factors; Treatment Outcome; Vincristine | 2002 |
Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Idarubicin; Life Tables; Male; Melphalan; Mercaptopurine; Middle Aged; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Retrospective Studies; Teniposide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Unusual implantation site of a port-a-cath system via the right femoral vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Mediastinal Neoplasms; Melphalan; Podophyllotoxin; Radiography; Thrombosis; Transplantation, Autologous | 2002 |
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Female; Humans; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate; Time Factors; Transplantation, Autologous; Vincristine | 2002 |
Acute myocardial ischemia after high-dose therapy with BEAM regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Melphalan; Middle Aged; Myocardial Ischemia; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Data Interpretation, Statistical; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Rhabdomyosarcoma; Sarcoma, Ewing; Sex Factors; Statistics, Nonparametric; Time Factors; Transplantation, Autologous; Vinblastine | 2002 |
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytokines; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; L-Lactate Dehydrogenase; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2003 |
[Bacteremia due to Capnocytophaga spp.: two cases].
Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Capnocytophaga; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning | 2003 |
[Foliculitis in a patient with Hodkins disease].
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Dermatomycoses; Dexamethasone; Doxorubicin; Etoposide; Folliculitis; Hodgkin Disease; Humans; Itraconazole; Malassezia; Male; Melphalan; Opportunistic Infections; Vinblastine | 2003 |
BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Rituximab; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
A hybrid form of myeloid/NK-cell acute leukemia and myeloid/NK-cell precursor acute leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; CD2 Antigens; Cytarabine; Flow Cytometry; Humans; Immunophenotyping; Killer Cells, Natural; Leukemia, Lymphoid; Male; Melphalan; Podophyllotoxin | 2003 |
A mathematical model for reconstitution of granulopoiesis after high dose chemotherapy with autologous stem cell transplantation.
Topics: Adult; Algorithms; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Differentiation; Cell Division; Computer Simulation; Cytarabine; Dose-Response Relationship, Drug; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Kinetics; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Models, Biological; Myelopoiesis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous | 2003 |
[Some improvements to our technic of cross beam centering by moulded apparatus].
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1953 |
Convergent beam roentgen tube.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1955 |
Preliminary experiences with a 50 gram converging beam radium unit.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radium | 1955 |
[Centering of the beam in pendulum cyclotherapy and in convergent pendulum cyclotherapy].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiotherapy | 1958 |
[Stratigraphy with thick and thin layers in various changes of the beam direction].
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; Radiography | 1961 |
Beam flatteners for a teletherapy unit.
Topics: Carmustine; Cytarabine; Equipment and Supplies; Etoposide; Humans; Melphalan; Radiotherapy | 1961 |
A method of multilead D.C. registration on the one-beam oscilloscope by the chopping technique.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Oscillometry | 1961 |
Moving beam irradiation in orthovoltage radiotherapy.
Topics: Carmustine; Cytarabine; Etoposide; Humans; Melphalan; Radiotherapy | 1962 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Safety; Salvage Therapy; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2003 |
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Salvage Therapy; Treatment Outcome | 2004 |
High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Prognosis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
A long-term follow-up of 33 patients with non-Hodgkin's lymphoma who received the BEAM high-dose intensification regimen with cytokine support only and no transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Therapy, Combination; Erythropoietin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Survival Rate; Time Factors | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contraceptives, Oral, Synthetic; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunotherapy; International Normalized Ratio; Lynestrenol; Melphalan; Mineralocorticoid Receptor Antagonists; Risk; Risk Factors; Time Factors; Venous Thrombosis; Warfarin | 2005 |
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Melphalan; Middle Aged; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Quality of Life; Radiography; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2005 |
Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Melphalan; Middle Aged; Multivariate Analysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2005 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Poland; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2004 |
[Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Etoposide; Humans; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Treatment Outcome | 2004 |
Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Salvage Therapy; Transplantation, Autologous; Transplants | 2005 |
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cattle; Complex Mixtures; Cytarabine; Dose-Response Relationship, Drug; Female; Growth Substances; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Milk; Mouth Mucosa; Mouthwashes; Podophyllotoxin; Stomatitis | 2005 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Medical Oncology; Melphalan; Middle Aged; Prednisolone; Prognosis; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous | 2006 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Remission Induction; Retrospective Studies; Transplantation, Autologous | 2006 |
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.
Topics: Administration, Oral; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Cytarabine; Female; Hemorrhage; Humans; Male; Melphalan; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Retrospective Studies; Risk Factors; Transplantation, Homologous; Venous Thrombosis; Warfarin | 2006 |
Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Incidence; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Oral Ulcer; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Sex Factors; Stomatitis; Transplantation, Autologous | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Melphalan; Recurrence; Salvage Therapy | 2006 |
Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Transformation, Neoplastic; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Transfusion; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; Rituximab; Time Factors; Vincristine | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
Autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Diarrhea; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Liver Diseases; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Mucositis; Multiple Sclerosis; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Topics: Acrylamides; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Combinations; Humans; K562 Cells; Leukemia, Myeloid, Acute; Melphalan; Methylnitronitrosoguanidine; Monocytes; NAD; Piperidines | 2006 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation; Follow-Up Studies; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Immunoglobulin Heavy Chains; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Vincristine | 2006 |
Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Kinetics; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2007 |
[What is your diagnosis? Neutropenic colitis (neutropenic typhlitis)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cecum; Colon; Combined Modality Therapy; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Tomography, X-Ray Computed; Typhlitis | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Transplantation, Autologous | 2007 |
Palifermin and palmar-plantar erythrodysesthesia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Hypersensitivity; Female; Fibroblast Growth Factor 7; Foot Dermatoses; Hand Dermatoses; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Mitogens; Podophyllotoxin | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Data Interpretation, Statistical; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Follow-Up Studies; Hodgkin Disease; Humans; Melphalan; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
[Transdermal fentanyl in treating severe painful mucositis caused by autologous hematopoietic stem cell transplantation].
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Fentanyl; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Pain; Pain Measurement; Podophyllotoxin; Quality of Life; Transplantation, Homologous; Young Adult | 2007 |
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Podophyllotoxin; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Rituximab; Survival Rate; Vincristine | 2007 |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Transplantation, Autologous; Treatment Outcome | 2007 |
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Staging; Podophyllotoxin; Prognosis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2007 |
BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Survival Rate; Transplantation, Autologous | 2008 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine | 2007 |
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Etoposide; Female; Humans; Immunoblastic Lymphadenopathy; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Treatment Outcome | 2008 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Stomatitis; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Confusion; Cryoprotective Agents; Cytarabine; Dacarbazine; Dexamethasone; Dimethyl Sulfoxide; Doxorubicin; Etoposide; Hippocampus; Hodgkin Disease; Humans; Hyperventilation; Ifosfamide; Magnetic Resonance Imaging; Male; Melphalan; Paresthesia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Vinblastine; Vision Disorders | 2008 |
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome | 2008 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2008 |
Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Graft Survival; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Severity of Illness Index; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsule Endoscopy; Carmustine; Cytarabine; Female; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Male; Melphalan; Middle Aged; Mucositis; Podophyllotoxin; Transplantation, Autologous | 2008 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Distribution; Cohort Studies; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Risk; Statistics, Nonparametric; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Medical Audit; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Risk Factors; Stem Cell Transplantation; Stomatitis; Transplantation Conditioning | 2009 |
The development of a beam-walking test and its use in measuring development of balance in children.
Topics: Carmustine; Child; Cytarabine; Etoposide; Growth and Development; Melphalan; Walking | 1947 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
Pseudo-bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantation.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carmustine; Cisplatin; Colitis; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Intestinal Pseudo-Obstruction; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Postoperative Complications; Prednisolone; Rituximab; Transplantation, Autologous; Vincristine; Virus Activation | 2009 |
Autologous stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of three cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Lymphoma, AIDS-Related; Male; Melphalan; Nitrosourea Compounds; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2009 |
Mass selection of ions from beams using waveform isolation in radiofrequency quadrupoles.
Topics: Carmustine; Cytarabine; Ions; Mass Spectrometry; Mathematics; Melphalan; Radio Waves; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult | 2009 |
Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Salvage Therapy; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2009 |
[One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; International Cooperation; Kaplan-Meier Estimate; Leiomyosarcoma; Lymphoma, Non-Hodgkin; Melphalan; Multiple Myeloma; Nitrosourea Compounds; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2009 |
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Podophyllotoxin; Prednisone; Prognosis; Prospective Studies; Protein Processing, Post-Translational; STAT3 Transcription Factor; Transplantation, Autologous; Tumor Suppressor Protein p53; Vincristine | 2009 |
Successful bortezomib-based treatment in POEMS syndrome.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Depression, Chemical; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; Male; Melphalan; Plasma Cells; POEMS Syndrome; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Italy; Lymph Nodes; Male; Melphalan; Middle Aged; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2002 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematology; Humans; Italy; Lymphoma, Non-Hodgkin; Melphalan; Podophyllotoxin; Practice Guidelines as Topic; Recurrence; Societies, Medical; Time Factors | 2010 |
Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Carmustine; Cell Count; Child, Preschool; Combined Modality Therapy; Cryopreservation; Cyclophosphamide; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunomagnetic Separation; Leukapheresis; Lymphoma, Large-Cell, Anaplastic; Melphalan; Podophyllotoxin; Recurrence; Transplantation, Autologous | 2010 |
Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Manitoba; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiation Pneumonitis; Retrospective Studies; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation; Young Adult | 2010 |
High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Kaplan-Meier Estimate; Male; Melphalan; Multiple Sclerosis; Treatment Outcome | 2010 |
Simultaneous bilateral spontaneous pneumothorax following high-dose chemotherapy and bone marrow transplantation for mantle cell lymphoma without evidence of pulmonary disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Lung Diseases; Lymphoma, Mantle-Cell; Melphalan; Middle Aged; Pneumothorax; Prognosis | 2010 |
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Cytokines; Female; Herpesvirus 1, Human; Herpesvirus 2, Human; Hodgkin Disease; Humans; Inflammation; Interleukin-1; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Saliva; Severity of Illness Index; Statistics as Topic; Stem Cell Transplantation; Stomatitis; Transplantation, Autologous; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
A novel N-hydroxy-N'-aminoguanidine derivative inhibits ribonucleotide reductase activity: Effects in human HL-60 promyelocytic leukemia cells and synergism with arabinofuranosylcytosine (Ara-C).
Topics: Cell Cycle Proteins; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Guanidines; HL-60 Cells; Humans; Immunoglobulin G; Melphalan; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship | 2011 |
Absorption measurements for broad beams of 1- and 2-million-volt X-rays.
Topics: Carmustine; Cytarabine; Etoposide; Melphalan; X-Rays | 1946 |
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hodgkin Disease; Humans; Length of Stay; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Severity of Illness Index; Thrombocytopenia; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2010 |
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Piperazines; Pyrimidines; Tumor Stem Cell Assay | 2011 |
FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Trials, Phase I as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Male; Melphalan; Prednisone; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2012 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmustine; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Humans; Ifosfamide; Incidental Findings; Lung Diseases; Lymphatic Diseases; Marijuana Smoking; Melphalan; Methylprednisolone; Mitoguazone; Remission Induction; Smoking; Tomography, X-Ray Computed; Vinblastine; Vindesine; Vinorelbine; Young Adult | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin's lymphoma resistant to platinum-containing first-line salvage chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2012 |
Single-dose pegylated-filgrastim versus daily filgrastim after high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies: delayed platelets recovery?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Young Adult | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Compassionate Use Trials; Crizotinib; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Humans; Immunoconjugates; Lymphocyte Transfusion; Lymphoma, Large-Cell, Anaplastic; Male; Melphalan; Molecular Targeted Therapy; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Prednisone; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Transplantation, Homologous; Vincristine | 2013 |
Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cytarabine; Female; HIV Seropositivity; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Modified BEAM conditioning regimen in patients with Hodgkin and non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Melphalan | 2012 |
Successful allogeneic stem cell transplantation for Lennert lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Melphalan; Methotrexate; Middle Aged; Nitrosourea Compounds; Pharyngitis; Prednisolone; Recurrence; Rituximab; Salvage Therapy; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 2013 |
Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Podophyllotoxin; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Melphalan; Middle Aged; Mucositis; Peripheral Blood Stem Cell Transplantation; Preoperative Care; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustine; Chemoradiotherapy; Cisplatin; Cohort Studies; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Young Adult | 2015 |
Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Risk Factors; Transplantation, Autologous; Young Adult | 2013 |
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; C-Reactive Protein; Carmustine; Case-Control Studies; Cytarabine; Etoposide; Febrile Neutropenia; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Inflammation; Intestinal Mucosa; Male; Melphalan; Middle Aged; Mucositis; Neutropenia; Young Adult | 2014 |
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2014 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Radiation; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2013 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Carmustine; Central Nervous System Neoplasms; Cesarean Section; Cytarabine; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Magnetic Resonance Imaging; Melphalan; Methotrexate; Podophyllotoxin; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Rituximab; Transplantation, Autologous; Treatment Outcome | 2014 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous | 2014 |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Registries; Retrospective Studies | 2014 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cytarabine; Drug Evaluation; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Radionuclide Imaging; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Lomustine use in combination with etoposide, cytarabine and melphalan in a brief conditioning regimen for auto-HSCT in patients with lymphoma: the optimal dose.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Transplantation Conditioning; Young Adult | 2014 |
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2014 |
Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2014 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult | 2014 |
Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Carmustine; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melphalan; Nitriles; Nitrogen Mustard Compounds; Prednisone; Primary Myelofibrosis; Pyrazines; Pyrazoles; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Rituximab; Vincristine | 2014 |
Primary central nervous system lymphoma in an immunocompetent 12-year-old boy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basal Ganglia; Brain Neoplasms; Child; Cytarabine; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Radiography; Thalamus; Thiotepa; White Matter | 2014 |
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Doxorubicin; England; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Melphalan; Menopause, Premature; Ovary; Poisson Distribution; Proportional Hazards Models; Radiotherapy Dosage; Risk Assessment; Surveys and Questionnaires; Vinblastine; Wales; Young Adult | 2014 |
The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Allografts; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Marrow Transplantation; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Societies, Medical; Survival Rate; Transplantation Conditioning; United Kingdom | 2015 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2015 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Dog Diseases; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Histiocytic Sarcoma; Melphalan; Methotrexate; Nimustine; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vincristine | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Matched-Pair Analysis; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting | 2016 |
Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Risk; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2015 |
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous | 2015 |
Fertility After Treatment With High Dose Melphalan in Women With Acute Myelogenous Leukemia.
Topics: Adolescent; Adult; Anthracyclines; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Survivors; Transplantation Conditioning; Young Adult | 2016 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carmustine; Creatinine; Cytarabine; Disease-Free Survival; Etoposide; Female; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Serum Albumin; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Humans; Male; Melphalan; Middle Aged; Mucosal-Associated Invariant T Cells; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Evaluation; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Nitrosourea Compounds; Organophosphorus Compounds; Positron-Emission Tomography; Prospective Studies; Registries; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2016 |
Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Podophyllotoxin; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa | 2016 |
LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
Topics: Adolescent; Adult; Autografts; Carmustine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lomustine; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Retrospective Studies; Survival Rate; Transplantation Conditioning; Young Adult | 2016 |
Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Podophyllotoxin; Premenopause; Retrospective Studies; Transplantation Conditioning; Young Adult | 2016 |
Thymic Activity and T Cell Repertoire Recovery after Autologous Hematopoietic Stem Cell Transplantation Preceded by Myeloablative Radiotherapy or Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Thymus Gland; Transplantation Conditioning; Whole-Body Irradiation | 2016 |
Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Californium; Carmustine; Combined Modality Therapy; Cytarabine; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Treatment Outcome | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult | 2016 |
Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2016 |
Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; France; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2016 |
A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lomustine; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
[Efficacy Comparison of Low dose Thalidomide Combined with Modified VCMP and VAD regimens for Treatment of Aged MM Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prednisone; Remission Induction; Survival Rate; Thalidomide; Thrombocytopenia; Vincristine | 2016 |
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Febrile Neutropenia; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Nausea; Nitrosourea Compounds; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hodgkin Disease; Humans; Male; Melphalan; Neoplasm Metastasis; Podophyllotoxin; Programmed Cell Death 1 Receptor; Remission Induction; Salvage Therapy | 2016 |
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cost-Benefit Analysis; Cytarabine; Female; Follow-Up Studies; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Infections; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2016 |
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Female; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Melphalan; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Phenylalanine; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carmustine; Cryptococcosis; Cryptococcus; Cytarabine; Diarrhea; Etoposide; Feces; Fluconazole; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Microbial Sensitivity Tests; Transplantation Conditioning; Transplantation, Autologous; Voriconazole | 2017 |
Synthesis of dual-action parthenolide prodrugs as potent anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Line, Tumor; Chemistry Techniques, Synthetic; Cytarabine; Humans; Lactones; Melphalan; Neoplasms; Prodrugs; Sesquiterpenes | 2017 |
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Radioimmunotherapy; Retrospective Studies; Rituximab; Survival Analysis; Transplantation, Autologous; Young Adult | 2017 |
A dexamethasone, melphalan, actinomycin-D and cytarabine chemotherapy protocol as a rescue treatment for feline lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cytarabine; Dactinomycin; Dexamethasone; Female; Lymphoma; Male; Melphalan; Salvage Therapy | 2018 |
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 2018 |
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Lymphoma, Mantle-Cell; Male; Melphalan; Organoplatinum Compounds; Syndrome | 2018 |
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Prednisone; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine | 2018 |
Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carmustine; Cost-Benefit Analysis; Cyclophosphamide; Cytarabine; Etoposide; Female; HIV Infections; Humans; Ifosfamide; Male; Melphalan; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Analysis | 2018 |
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Young Adult | 2018 |
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2018 |
Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Infusion Pumps; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Outpatients; Podophyllotoxin | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2018 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cetuximab; Cytarabine; ErbB Receptors; Etoposide; Genotype; Humans; Intestinal Neoplasms; Liquid Biopsy; Male; Melphalan; Paranasal Sinus Neoplasms | 2019 |
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning | 2019 |
Evaluation of a multi-agent chemotherapy protocol combining dexamethasone, melphalan, actinomycin D, and cytarabine for the treatment of resistant canine non-Hodgkin high-grade lymphomas: a single centre's experience.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Dactinomycin; Databases, Factual; Dexamethasone; Dog Diseases; Dogs; Female; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Schools, Veterinary; Thrombocytopenia; Treatment Outcome; United Kingdom | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2019 |
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Renal Insufficiency; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning | 2019 |
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Induction Chemotherapy; International Cooperation; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2019 |
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cytarabine; Female; France; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Herpes zoster after autologous haematopoietic stem cell transplantation without antiviral prophylaxis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Herpes Zoster; Humans; Melphalan; Middle Aged; Podophyllotoxin | 2019 |
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Survival Rate; Transplantation, Autologous; Waldenstrom Macroglobulinemia | 2019 |
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Podophyllotoxin; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2019 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Prospective Studies; Retrospective Studies; Transplantation, Autologous | 2020 |
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multivariate Analysis; Registries; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Treatment Outcome; Young Adult | 2020 |
Successful Umbilical Cord Blood Transplantation With Reduced-intensity Conditioning for Acute Myeloid Leukemia in a Child With Shwachman-Diamond Syndrome.
Topics: Antineoplastic Agents, Alkylating; Child; Cytarabine; Female; Fetal Blood; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Melphalan; Myeloablative Agonists; Shwachman-Diamond Syndrome; Transplantation Conditioning; Vidarabine | 2021 |
Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Vessels; Carmustine; Cyclophosphamide; Cytarabine; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Early Detection of Cancer; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Podophyllotoxin; Prednisone; Rituximab; Skin; Skin Neoplasms; Treatment Outcome; Vincristine | 2020 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2020 |
BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Progression-Free Survival; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
Topics: Adult; Busulfan; Cladribine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Melphalan; Mitoxantrone; Salvage Therapy; Transplantation Conditioning | 2020 |
Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Humans; Lomustine; Lymphoma; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Bendamustine-induced nephrogenic diabetes insipidus - A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Diabetes Insipidus, Nephrogenic; Diabetes Mellitus; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Transplantation, Autologous | 2022 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning | 2021 |
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients' outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Neoplasm Recurrence, Local; Neutrophils; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2022 |
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Melphalan; Retrospective Studies; Transplantation, Autologous | 2022 |
Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Semustine; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Comparison of CEAC, BEAM and IEAC conditioning regimens followed by autologous stem cell transplantation in peripheral T-cell lymphoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2022 |
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
Topics: Antilymphocyte Serum; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin Heavy Chains; Melphalan; Multiple Sclerosis | 2022 |
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Transplantation, Autologous | 2023 |
Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2023 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |